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ABSTRCT
High frequencies of Cf recognizing laboratory strains of HIV - 1 are present in
Hrv' - 1 infected adults as early as preseroconversion. The presence of mv - 1 specific 
during primar infection has been corrlated with better control of early virmia and a more
delayed onset of CD4 lymphocyte loss. Previous experients in our laboratory have
demonstrated that, unlike HI - 1 infected adults , the majority of vertcaly infected infants
lack CTL which recognize laboratory strains ofHI- l withn the first year of life, ADC
antibody responses against laboratory strains of HIV - 1 env gene products ar also de1ayp,d
unti at least two years of age. As a possible correlate, disease progression is also more
rapid in vertcally infected infants.
We hypothesized that mv - I-specific Cf are type-specific in early infancy and that
the use of target cells expressing laboratory strain gene products might limit the detection. of
HIV- l-specific CTL. To address this hypothesis, HIV- l env genes from early isolates of
four infants were PCR amplified, cloned, and used to generate recombinant vaccinia
vectors (vv). The frequencies of Cf precursors (CTLp) recognizing env gene products
from autologous isolates and the nIB strain of HIV - 1 were measured at tie points from
early infancy to 19 months using limiting dilution analysis (LDA). ADC titers were also
measured against autologous and nIB env gene products at 4 tie points spanning 2
months to 2 years of age.
CT precursors from 3 of 4 of these patients were specific only for autologous
HIV- l env gene products during the first 6 to 12 months of age. A pattern of 
responsiveness was observed in these 3 patients in which type-specific CI precursors
observed in early infancy were replaced by cross-reactive, group-specific CT by 6 to 12
months of age. CTL precursors from a fourth patient at 12 months of age recognized nIB
env and lout of 2 envs derived from 2 autologous viral isolates.
High titers titers of ADCC antibodies agaist autologous env were detected
in two infants prior to the detetion of ADC antibodies to HIB. In two other infants
group specific ADCC antibody responses were detected in late infancy.
Our results demonstrate that young infants can mount mv - 1 specific Cf and
ADCC responses. The abilty of young infants to mount cellular imune responses to
HIV - 1 also provides support for the concept of periatal vaccination to prevent mV-
transmission. Furtennore, the lack of broadly-reactive Cf in early infancy suggests that
the use of vaccines based on laboratory strains of HIV - 1 may not aford protection from
vertical infection.
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CHAPTR 1. INRODUCTION
A. General Characteristics of HIV - 1 Infection
Since 1983 , when the first strain of HIV - 1 was identified and sequenced by Gallo
and Montagnier, a multitude of strains of ID - 1 have been isolated and sequenced from
infected individuals and categorized on the basis of their degree of nucleotide identity.
From this data it was observed that individual. HI -1 strains taen from a parcular
geographic location were closely related and therefore were organzed into "c1ades" based
upon ths similarty. As a result, parcular HI- l1aboratory strains have been considered
to be representative of the clade as a whole and used to study ID - I-specific immune
responses within individuals suspected to be infected with viral strains of that clade. For
example , the II (LA V) strain of HIV - , first isolated in 1983 from a.'1 infected individual
in the USA has been used extensively as a representative North American clade B strain
virus to measure HI - I-specific immunity among individuals infected with mv - 1 while in
. . 
the USA.
Sequence identity of HIV - 1 strains worldwide is between 85-97% (1), however,
the greatest degree of diversity exists within the env gene of the virus. Sequence varation
within the env gene can even be detected within viral variants sequenced from a single
infected individual. These varants arise in an individual from continuous replication of the
virus along the course of infection and have been detected using nucleotide sequence or
heterodup1ex mobility analyses (2). Diversifcation of the vir population during infection
is a result of nucleotide substitutions
, deletions , insertions or duplications witr.in the viral
genome which occur due to the low fidelity of reverse transcriptase and by viral
recombination. The degree of nucleotide divergence over the entire genome among
isolates from one individual is approximately 6 to 10%. Withn the env gene product itself
however, independent isolates have been demonstrated to differ in almost 10% of amno
acid residues among North American patients and by as much as 26% among independent
HIV - 1 Afcan isolates (3). The rate of evolution of the HIV - 1 env gene in an infected
individual has been estimated to be ten fold faster than that estiated for the gag gene (4).
Furtermore, the nucleotide changes seen within the env gene of individual isolates involve
insertons , deletions or duplications rather than the point mutations observed in the IllV-
gag gene (1). The degree of heterogeneity within the env gene has been used to detennne
intrapatient and interpatient viral diversity.
The env gene product is a precursor po1yprotein designated gp160 which becomes
cleaved into gp120 and gp41 , representing the surface and transmembrane subunits of the
mature env glycoprotein complex, respectively. The precursor env protein is synthesized
and glycosy1ated in the rough endoplasmic reticulum of the infected cell. Fol1owillg
synthesis, the glycoproteins oligomerize and are transported into the Golgi where they are
cleaved into gp120 and gp41. It is also within the Go1gi where many of the high mannose
1inked oligosaccharde side chains ar modified. The resulting proteins ar so heavily
glycosy1ated that 50% of the molecular mass of gp120 is composed of oligosacchardes
(1). A greater degree of variability is present within the gp 120 encoding region of the gene
in which five regions of relative conservation (CI-C5) are interrpted by five regions of
hypervarabi1ity (Vl- V5).
A high rate of HIV - 1 replication throughout infection is needed to generate and
maintan the complexity of the viral varant population observed in infected individuals.
With the use of anti-retroviral drugs which strongly suppress viral replication
, Wei et al (5)
and Ho et al (6) demonstrated the rapid turnover of HIV- l within the plasma of infected
individuals. They demonstrated almost complete suppression of de novo infection by these
anti-retroviral drugs which allowed them to calculate a 2 day half-life of the remaining
virion population within the plasma. Plasma virus was shown to derive primary from de
novo rounds of replication withn a short-lived, unknown population of cells whose half-
life could not exceed that of the virus. PBMC were therefore not considered to contrbute
significantly to ths plasma pool of virus because they ar longer lived. These studies
showed that PBMC were turned over at a constant rate which suggested that progressive
CD4 cell loss was due to continual de novo infection of PBMC. The maintenance of a viral
load "steady state" in infected patients from a rage of 10 to 10 virons per rn (7) must
therefore require high levels of viral infection and production. It is ths dynamc process of
continual infection and replication which contrbutes to the generation of viral varants.
The evolution of viral varants also occurs from selective pressures within the host.
A strong immune response against a parcular regi'On of a ID - 1 gene product might result
in a selection of varants caring withn ths region a mutation which can escape
recognition. ID- l env , because it is a target of both cellular and humoral immunity as
well as a detennnant of viral tropism, is parcularly afected by selective pressures. This
is paricularly applicable to the protein' s V3 loop which contains at least thee known CTL
epitopes (8 , 9) and is considered to be the principal neutralizing domain of the virus. Vir
mutations have been reported within the V3 loop which weaken or abrogate 
recognition (10- 13) and recognition by neutralizing antibody (14). As an example of
selective pressures applied by CI on HIV- l variation, nef Cf escape mutants were
generated and disease progression was observed following the transfer of HIV - 1 nef-
specific autologous Cf to an AIS patient (13). Following infusion of these CTL, nef
varant sequences emerged with mutations in the CTL epitope which were accompaned by
a rise in viral load.
The viral varants which evolve within an individual are not only genotypically
distinct but also demonstrate phenotypic differences. These include replication rate
susceptibility to neutralizing and enhancing antibodies, tissue tropism and ability to induce
syncytia (15). In addition, studies in which viral varants have been analyzed at different
points of infection suggest that the presence of parcular phenotypes appears to relate to
disease progression. For example, vir isolates taen from asymptomatic patients appear
to replicate more slowly and to lower titers in tissue culture, whereas , viral isolates from
AIS patients appear to replicate more rapidly, to higher titers
, to establish persistent
infection in lymphoid and monocytoid cell lines and to induce syncytia formation.
In the majority of adults during primar infection and vertcally infected infants
withn the fIrst few months of life , the viral varant populations appear to be homogeneous
in regard to both genotype and phenotype. Zhu et al (16) characteried the phenotypic and
genotypic characteristics of HI - 1 varants within five seroconverters. The varants withn
each individual were phenotypically identical and were macrophage tropic and non.,
syncytia-inducing. In addition, env gene sequences from V3 to V5 of viral varants withn
each individual were greater than 99% similar compared with 90% to 94% simlarty in the
chronically infected transmitters. De1war et al (17) using heteroduplex mobility and
tracking analyses (2), also demonstrated a strong conservation of sequence within isolates
present during primar infection. In addition, Wolinsky et al (l8) sequenced, the V3 and
V 4- V5 regions of several varants from vertcally infants from two to four months of age.
Similar to the findings in adults, these varants were relatively homogeneous.
B. Clinical course of HI V-
The clincal course of HIV - 1 can be divided into two phases: a primar infection
phase and a chronic phase. In primar HIV - 1 infection, high 1evc1s of virus can be
detected (7) in the plasma which reach a peak and then subside within weeks of infection
and are maintained at a lower level. This subsequent lower level of virus is reported to
range from 10 to 10 virions per rn of plasma (7) demonstrating that a high quantity 
virus is stil maintained. The initial drop in plasma viremia, in adults, generally co-incides
with the induction of humoral and cellular immunity. A clicaly latent state ensues in
which continual ID - 1 replication is accompaned by HIV - 1 specific imune responses;
parcularly by CT. Ths characteries the chronic phase of ID- l infection. Eventually,
in most patients, the CD4 pool of T lymphocytes becomes depleted with a concorntant
severe immunodeficiency. The period of c1inicallatency is varable, but generally lasts for
approximately 10- 12 years. Recent reports have uncovered a population of individuals
however, in which CD4 depletion and disease progression have not occUled altltough they
have been infected beyond the average amount of tie withn which one would expect to
observe disease (19-22).
C. HIV -1 specific immunity
Studies of cell-mediated HIV-specific imune responses of infected individuals
reveal the presence of high levels of ID -specific Cf activity withn the peripheral blood
of the majority of infected individuals (23- 8). . An unusual feature of HIV infection is the
ease with which CI activity against viral antigens can be measured during the
asymptomatic period directly from freshly isolated PBLs in the absence of prior in vitro
stimulation. High frequencies of Cf precursors have been quantitated from PBMC as
well. Koup et al (29) quantitated HIV - I-specific CTL within the PBMC of patients during
and three to six months following primar infection. The frequencies of mv - I-specific
CT precursors were reported to be within a range previously reported in chronica!ly-
infected patients: from 30 to 3800 per 10 PBMC (30-32). Cf activit'j has been
demonstrated against both strctural and nonstrctural viral antigens (10, 33-35). The
effector cell phenotype, characterized through antibody blocking experiments and depletion
studies , is a CD8 and class I-restricted cytotoxic T cell. However
, recognition of target
cells expressing the env gene appear to be mediated though both class I-restrcted and
non-HLA-restrcted effector mechansms, such as ADCC.
Two recent and separate studies provide compellng evidence for the role of Cf 
primar infection. In these studies the development of ID -specific Cf were examed
during primar infection and correlated with viral load (29, 36). Both studies measured the
viral loads and Cf precursors of HIV - 1 infected patients from seroconversion to six
months. Presence of ID - I-specific CI was associated with a decline in the intial
viremia, whereas, lack of ths CI response appeared to corrlate with higher viral loads.
In addition to ths recent data, prior studies have also demonstrated the abilty of autologous
CD8+ lymphocytes to inhbit ID replication in PBL of infected individuals in vitro (37-
39). Studies using an an model also support the hypothesis that Cf may be
protective in HI infection. Multiple adoptive transfers of nef-specific Cf clones into
PBL-reconstituted SCID mice (hu-PBL-SCID) just prior to and following HI chalenge
was shown to protect against infection in a majority of the mice receiving these clones (40).
Humoral responses dircted at parcular regions of the env gene can dict virus
neutralization. The primar neutrzing domain of env is considered to be the V3 loop.
- _ . -
Antibodies diected to this region in inected individuals have been able to neutrize
heterologous strains of HIV- l in vitro (41-43). However, monoclonal antibodies against
the CD4 binding domain within C4 (44, 45), regions within V2 (46)and discontinuous
epitopes within env which can(47, 48) and cannot inhibit CD4 binding (49) have also ben
shown to neutralize the virus in vitro.
Anal models of HIV - infection provide evidence for a possible role of
neutralizing antibody for protection when passively transferred prior to infection (50)
However, there does not appear to be a strong correlation between the presence or absence
of these antibodies and protection in natural infection. Neutralizing antibody responses
have been reported to occur shortly after serocollversion and appear to be isolate-specific
(51). Neuu:alizing antibody may therefore contrbute to the clearng of early viremia, The
specificity of this response apparently broadens over time as antibody which can neutralize
heterologous laboratory strains can be detected although these antibodies are present at low
titers. It has been demonstrated that with the progression of inection withn an individual
antibodies may be capable of neutralizing laboratory strans of HIV - , while they may not
be able to neutr autologous virus (14, 51). The presence of neutration escape
mutants implies that neutralizing antibodies are exertng selective imune pressure in vivo.
It therefore seems liely that this response serves a protective role although no clear
correlation has been made between its presence and viral load.
The env gene of mv - 1 can also serve as a taget for ADCC. This is an immune
mechanism whereby lysis of infected cells is effected by the binding of antibody attached to
NK cells via the Fc receptor to the env glycoprotein on the surface of the cell. This is
therefore , a humoral response diected solely at cell-associated virus. ADCC-mediating
antibodies have been demonstrated in HIV- l infected individuals (52-54). ADCC antibody
epitopes have been mapped to both gp120 and gp41(55, 56).
The role of ADC antibody in control of HIV - 1 replication is perhaps the least
well-defined. The most notable example of a protective role for ADC in viral infection is
a murine model of vertcal transmission, of Herpes Simplex Virus. Transfer of ADC
mediating antibody into neonatal mice in the presence or absence of murie or human
effector cells resulted in protection of HSV -susceptible 
mice (57, 58). ADCC antibodies in
adult humans may also playa role in controllng early viremia in HIV - 1, as they are of the
first humoral responses to be detected (59) and demonstrate broader reactivity prior to that
of neutralizing antibody. However, ADCC antibody effectiveness has not been extensively
studied in HIV -1 infection. ADCC could be importt in the elimination of cell-associated
virus and could work in concert with CTL in this endeavor.
D. Vertcal transmission ofID-
The majority ofID- infected children have become so though vertcal (matemal)
transmission of the virus. Withn the United States alone, HIV- l infection is the seventh
leading cause of death among children 1 - 4 year old and ran much higher in developing
countres (60).
Transmission of HIV - 1 to the fetus can occur during gestation. The mechansm of
in utero transmission is not well understood. One hypothesis is that a placenta disruption
such as infection, can allow for the contact of maternal and feta lymphocytes (61, 62).
Hofbauer cells, which are monocytes of fetal origin located on the fetal side of the placenta,
have been theorized to be a target for infection. Another possibilty is that IgG comp1exed
with virs is allowed entr into the feta circulation though trsplacental transfer of
maternal immunoglobulin. Transmission can also occur during birth. During labor and
delivery, mucosal surfaces of the neonate are exposed to maternal blood and cervico-
vaginal secretions. Postparum transmission of HIV - 1 can also occur through breast milk.
Breast milk transmission is less likely to occur in the United States where, if HIV-
positivity is known , mothers are counselled to avoid breast feeding.
Diagnostic standards have been agreed upon to determne the timing of HIV-
infection in infants (63). Detection of virus by culture or DNA PCR within 48 hours of
birt with additional positive cultures and DNA PCR subsequent to this tie defines the
infection as having occurred in utero. PBMC from infants which are negative for viral
culture and PCR within the first week of life but subsequently are 
repeatedly positive are
considered to have been infected in the intraparum period.
Similar to the adult pattern of acute infection , infants experience a burst of viremia
which occurs between the third and sixteenth week of life, regardless of the timing of
infection. However, unlike adult infection , the majority of infants undergo a more rapid
course of disease progression than adults. In a period between 1981- 1992, greater than
44% of perinataly infected infants had AIS diagnosed within their first year of life as
reported to the Centers for Disease Control (63)
E. Infant ID - 1 specific immunity
1. TL. Detetion of HIV - 1 specific CI in early infancy is rae and usually
requires in vitro stiulation of PBMC. Afer 12 months of age, Cf responses become
more prevalent, but, the detection stil requires in vitro stimulation in a majority of children.
This is in direct contrast to CTL detection in adults. Luzuriaga et a1 (64), measuring mV-
gag-specific CT directly from peripheral blood taen from 12 vertcally infected infants 6
to 30 months of age, detected responses in only 3 of these individuals. Gag-specific 
responses were not detected in these individuals before 12 months of age. Buseyne et 
(65) measured cytolytc responses in HIV- l infected children of whom the majority were
greater than 12 months of age. Low level ID- l specific cytolysis was detected diectly in
freshly isolated PBMC of 70% of asymptomatic children. Only 20% of clinically
progressed children demonstrated CI responses in these prima.ry assays. In vitro
stimulation of these same PBMC using PHA and IL-2 for a period of 15-30 days resulted
in cytolytic activity against HIV- l withn all of the patients of both populations. Froebe1 et
al (66) studied a cohort of children of similar age and clincal status in which they detected
HIV - 1 specific CT following 9-23 days of in vitro stimulation using PHA and IL-
McFarland et al (67) also detected ell.. activity diectly from PBMC in only a smal
percentage of children over 12 months of age, but following nonantigen-specific in vitro
stimulation, were able to quantitate the number of Cf precursors withn this group.
These children demonstrated gag- and env-specific pCTL frequencies from 50-630/1 0
PBMC and from 66-3300110 PBMC, respectively. Studies within our laboratory, have
focused upon the Cf response within the first year of life. The majority of the infants
who were below 12 months of life lacked detectable HN 1 specific Cf responses withn
unstimu1ated PBMC (68). Although nonviral-specific stiulation allowed for detection of
CTL in some of these patients , others stil lacked measurable Cf responses even afer in
vitro stimulation. A notable finding withn this study was the detection of gag-specific
CTL precursors in the cord blood of one infant on the order of 333 pCTU10 PBMC. This
finding demonstrates the possibilty of fetal imune responses.
It is notable that al of the studies described above employed targets expressing
heterologous ID - 1 gene products derived from laboratory strains. The Cf recognition
and cytolysis of targets expressing HN- protein derived from autologous virus has not
been addressed.
Neutralizin antibod One cannot distinguish between IgG antibody of
maternal or infant origin within the first six months to a year of life. Therefore,
neutralzing antibody titers withn the mother during pregnancy have been examned
extensively in an attempt to find a correlation between transmission and neutralizing
- -
antibody titers. Husson et al (69) examned the transmission rate and maternal neutralizing
antibody titers against autologous matemal and infant viral isolates in a population of
women matched by CD4 percentage and use of zidovudine during pregnancy. Results of
this study indicated a positive correlation between low titers of autolgous neutralizing
antibody and an increased risk of transmission. Scarlatti et al (70) demonstrated simlar
results. Neutralizing antibody titers from sera flOm HN infected mothers were
quantitated against autologous and clinically-derived heterologous virus. Neutralizing
antibodies against autologous virus were more frequently detected in nontransmitting
women in this study. In addition, women who had measurable titers of neutralizing
antibody to autologous virus also were able to neutralize at least two heterologous viruses.
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Broliden et al (54) studied neutralizing antibody titers in 0 - 2 year old children in an
attempt to corrlate these titers with clincal outcome. Neutralizing titers against
heterologous viral strains (ilIB and RF were highest in patients who lacked any AIS
defining condition. Results of this study also demonstrate a lack of detectable neutring
antibody in these infants following loss of maternal antibody. However, neutralization was
not measured against autologous virs.
3. ADCC antibod In an attempt to corrlate additional ID- l-specific humoral
responses to the risk of vertcal transmission, ADC antibody titers have been quantitated
within infected transmittng mothers and compared with nontransmitters. Jenkins, et a1
(71), measured ADCC antibody titers against ID- um and -RF strains in mother-infant
pairs. Results of this study indicated that high levels of ADCC antibody did not correlate
with a decreased risk of transmission. Broliden, et al (54), also examned ADC antibody
titers to HIV- II and -RF in an attempt to correlate clinical outcome of HIV- l infection with
these titers. ADCC antibody was observed more frequently in non-AIS infants than in
those with AIS. Results of their study also demonstrated a lack of ADC antibody
against heterologous strains of HIV- l following clearce of maternal antibody. Using
II env expressing targets, we have also observed a lag in ADC antibody lysis unti at
least two years of age in HIV - 1 vertcally infected infants following clearance of mRternal
antibody. ADCC titers have not, however, been quantitated against autologous virus
where stronger correlations between both transmission and progression may be evident.
4. Summ of HI- l-s ecific immuni in verticall infected infants On the
basis of HIV - I-specific immune responses against laboratory strains of HIV - , vertcaly
infected infants appear to be deficient in CT responses within the first year of life and
ADCC antibody and neutralizing antibody responses within at least the first two years of
life. Table 1 is a comparson of HIV- l-specific immunity in adults and vertcaly infected
infants.
F. Hypotheses to explain lack ofHIV- l specific immunity in early infancy
Induction of tolerace Tolerance induction as a result of in utero or intraparm
aquisition of HIV - 1 infection is a possible explanation for the lack of detectable ID-
specific Cf during early infancy. A murine model of tolerance induction to viral antigen is
provided by that of mice exposed to lymphocytic choriomeningitis virus (LCM either in
utero or as neonates. LCMV -speific humoral immunity occurs during infection, but
LCMV -speific Cf cannot be detected following antigenic stimulation of spleen cells 
vitro, and a LCMV carer state is maintained (72). Tolerance to LCM can be reversed in
these animals if they are cleared of virus though adoptive transfer of LCMV 
-speific 
from immune animals. Upon subsequent challenge with LCMV, these anmals mount a
strong LCMV -specific cell mediated response. Tolerance induction may rely on factors
other than ting of transmission, such as the differing affinities possessed by different
HLA class I alleles for ID- l antigen. Yon Herrath et al (73) has demonstrated an HLA
class I allele-specific influence on thymic selection of LCMV -specific CTL. . In !!s study,
and H- mice were made transgenic for the NP gene of LCMV. This gene, under
expression of the Thy 1.2 promoter, was expressed in the thymus and peripheral T
lymphocytes of these mice. mice deleted their high affinity anti-LCMV-NP CTL but
generated equal number of lower-affinity CI of NP specificity. In contrast, H- mice
deleted all LCMV -NP-specific CTL, completely abrogating detection of these CTL.
Inabil to detect type-s ecific immuni with heterolo ous virus HIV - 1 specific
CTL and infant-derived ADCC and neutralizing antibody may be present within the first
year of life in vertcaly infected infants which have gone undetected due to assay
limitations. Most detection systems used to measure HIV - 1 specific immune responses
utilze genes from laboratory virus strains. Imune responses may be diected only to the
fairly homogeneous varant population observed in early infection. Lak of group-
specificity of cellular and humoral immune responses may account for their observed
absence in early infancy. Env responses would be expected to be the most type-specific of
al due to its varabilty between ID - 1 strains.
Immaturi or d sfunction of immune res onse The infant s imune system may
not be suffciently developed at the tie of infection to mount a virus-specific immune
response. The presence of high levels of Cf precursors in cord blood which we have
previously reported (6S) presents a strong argument against ths hypothesis unless immune
matuation was somehow linked to a differential effect of HIV - 1 viral replication in
individual patients. Valentin, et al (74) have proposed a mechansm whereby both CD4
and CD8 cells can be depleted in infants infected in utero. They demonstrate that trp1e-
negative (CD3- CD4- CD8-) thymocytes ar susceptible to infection. Infection of these
cells as well as double positive cells (CD4+ CDS+) could lead to an overa defect in T cell
function in these patients. A deficit in the ability of neonatal lymphocytes to proliferate and
produce interferon-gama in response to specific antigenic stimulation has been observed
in primar herpes simplex virus inection . (75). Furtherror , neonata lymphocytes
produce reduced levels of IF-y to a number of different stimuli (76 , 77) due to a decrease
in transcription of the IFN-y gene (78). Memory T cells, a subset of responding
lymphocytes, ar responsible for high levels of IFN-y production upon antigenic
stimulation (79). The low levels of IF-y produced by neonates may be due to the absence
of this subset of high T cell responders. Low CD40 ligand expression on neonatal T cells
has also been reported (SO). The CD40 ligand is a molecule responsible for ligating CD40
on the B cell to provide T cell help in immunoglobulin isotype switching. However, with
antigen stimulation in vitro, expression of this ligand increases , suggesting that the lower
expression in vivo is due to a antigen-naive population of T cells. A diminished ability of
infant NK cells, in comparson to adults, to mediate ADCC against HI -infected target
cells has also been reported (71). There ar conflcting data regarding the functional
maturity of cord blood lymphocytes. Haris et al (81) report that cord blood lymphocytes
do not repond well to in vitro stimulation using IL- , PHA or al1oantigens. On the other
hand, Stern et al (82) demonstrate PHA responsiveness withn the lymphocytes of cord
blood which is equivalent to that seen in older infants and adults. For that matter, PWM
and ConA responsiveness in cord blood appeared to be more vigorous than that seen at 10
months of age. The responses at 10 months of age to PWM and ConA were equivalent to
those of adults. The percentages of total T cells, T-cell subsets and B cells increased from
birh to later infancy and the CD4/CD8 ratio decreased. The percentage of CD8 cells was
lower in 10 month old infants in comparson with that of adults, therefore the CD4/CD8
ratio was stil higher at ths age than that of adults.
G. Objectives of this study
The ai of this study was to detenne whether infants vertcaly inected with
HIV - 1 ar capable of mounting an HIV - I-specific imune response against autologous
virus. The experimenta design employed to achieve this objective involved the
measurement of both cellular and humoral immunity through quantitation of Cf and
ADCC responses. These experiments were undertaken to detennne whether the
previously observed inability to detect mv - 1 specific CTL and ADCC responses within the
first year of life is due to type-specific immune responses or a complete lack of HIV-
specific cellular and humoral immunity.
Secondly, if autologous virs-specific responses were present, a second objective
was to examne the patterns of responsiveness over tie to two sequential isolates and to
examne the T cell responsiveness on a clonal level. Evaluation of patterns of
responsiveness could possibly provide clues as to how the imune response differs in
vertcally infected infants in comparson to infected adults.
mv - I-specific immunity may differ in infants infected in utero vs those infected
during the intraparm period due to a less matu imune system at the tie of infection
and the possibilty of neonata tolerance. Therefore, a fInal objective was to detennne
whether a difference existed in the capabilities of in utero versus intraparm infected
infants to mount HIV - 1 specific immune responses.
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Table 1. HIV - 1 specific imune responses against laboratory strains of HIV - 1 in adults
and vertically-infected infants and children
ADULT INFANT(..12 MO) CHILD (:: 12 MO)
CTp
+++
(29-32) (68)
++++
(67, 68)
Bulk II HI- (23-27)
+/-
(68) (65 , 68)
ADCC antibody
+ ++
(52, 53) (54, 71) (54)
Neutralizing antibody (83 , 84) (54 , 70) (54)
CHAR n. MATERI AN METHODS
A. Patients:
HIV - I-specific Cf responses were studied retrospectively in 4 HIV - 1 inected infants
whose clinical status was followed at the University of Massachusetts Medical Center. The
timing of HIV -1 infection was determned by previously established standards (85).
Patients VI-05 and VI-06 whose cord or neonatal lymphocyte samples were positive for
HIV - 1 by viral culture and/or DNA PCR were considered to have been infected in utero.
Patients VI-08 and VI- II were considered to have been inected during the intraparm
period. Lymphocyte samples were negative for HIV - 1 by viral culture and DNA PCR
prior to a month of age in these two patients. Al four patients demonstrated lI-
positivity upon subsequent repeated testing. Analyses of CI responses agaist the env
and gag gene products of the II strain of mv - 1 have previously been presented on these
four infants (68). Human Studies Commttee approval and individual infonned conseut
from each infant s guardian were obtained before \ye conducted th se studies. Table 2
describes the ages at which env genes were amplified from viral isolates and the virological
and clinical status of each patient.
B Reagents:
1. P1asmids: table 3
2. Primers: table 4 and 5
'--
Table 2. Time points at which env genes were derived from viral isolates and clical and
virological status of patients VI-05, VI- , VI-08 and VI- II.
Patient, Age at each time CD4% Absolute CD4 RNA* PBMC Drug
point culture:! therapy
VI-06, 1 d 1404 49,000
VI-06, 6 mog 000 yes
VI-05, 2 mo 3015 625
VI-05, 6 mo 1895
VI-08, 20 d 2091 125
VI-08, 6 mo 3611 254711
VI- , 1 mo 1754
VI- , 3 mo 2218
* RNA copies/rn plasma
* TCID J106 P!3MC
en v clones were derived from this tie point but en v recombinant vv were not
constructed
II data available only at 5 months of age
ND not done
Table 2. Time points at which env genes were derived from vir isolates and clical and
virological status of patients VI- , VI-06, VI-08 and VI- II.
HIV- l was cultured from infected PBMC from patients VI- , VI-06, VI-08 and VI- II at
the time points described. Supernatant from these cultures was used to establish infection
in donor PBMC and genomic DNA was extrcted and used as a template for PCR
amplification of the HIV -1 env gene as described in the Materials and Methods section.
The clinical status of the patient at these tie points is represented by the CD4 percentages
and absolute CD4 values. Virological status is represented by the viral RNA copy number.
Table 3. P1asmids
Plasmid Description
pNL4-
pCR3
pT2020
pAbT4587 A
pAbT4587
pAbT4603
full-length molecular clone of ID - 1; chimeric: 5' half is NY5 and 3' half
is LA V
In Vitrogen; eukarotic expression vector; T A clonig strategy; CMV promoter
Therion Biologics; pAbT4587 backbone with HN- MN env gene
Modified version of pAbT4587 (XhoI site in place of EcoRI
Therion Biologics; contains flanng nonessential vac sequences on either side
of cloning site; used to make recombinant vaccinia virs
Therion Biologics; pAbT4587 backbone with mV- l BHI0 env gene
Table 4. Primers for PCR:
Primer Designation Sequence Annealing
Position 
MNA GCGAAGAGCAGAAGACAGTGG 6197-6220
MN13 CAGCTCGTCTCA TTCTTCCC 8836-8857
209 ACCCCAACCCACAAGAAG 6453-6470
218 CTGTTAATAGTACIGG 7382-7399
* Oligonucleotide sequences described anneal within the HIV - 1 genome at positions based
upon published pNU-3 nucleotide positions (86).
Table 5. Primers for Sequencing:
Primer Designation Sequence Annealing
Position *
SP6 CA TACGATIAGGTGACACTATAG SP6 promoter
TAA TACGACTCACTATAGGAGA 17 promoter
MNA GCGAAGAGCAGAAGACAGTGG 6197-6220
210 GGITGGTCTGTGGTA 64-6461
209 ACCCCAACCCACAAGAAG 6453-670
212 ITA TCTCIA TGCGTG 6706-6723
214 GGAGTCTAGCAGAAGAA 7001-7018
215 TCTGGGTCCCCTCCTGAG 7306-7323
* Oligonucleotide sequences described anneal within the HIV -1 genome at positions based
upon published pNU-3 nucleotide positions (86).
C. Amplification of ID - 1 proviral DNA from infant isolates:
1. Viral Culture: Vir co-culture ' was set up from PBMC samples taen from
patient VI-06 at one day and 6 months of age, patient VI-05 at 2 months and 6 months of
age, patient VI-08 at 20 days and 6 months of age and patient VI-II at one month and the
months of age. Supernatants from these cultures were used to establish first passage viral
cultures in the following maner: 10 x 10 donor PBMC grown in 10% FCS and RPMI
and stimulated for 5 days with 5 U/ml IL-2 were pelleted and resuspended in 1 ml culture
supernatant and incubated at 37 C, 5% CO for 1 hour. The cells were washed to remove
input virus and resuspended in 10 ml RPMI, 10% FCS, 5 U/ml IL-2. Cultue supernatant
was sampled on day 3 and 5 and analyzed for p24 content. Second passage vir cultures
were also established in the same manner.
2. Genomic DNA extrction: Approximately 10 x 10 cells from the viral cultures
were pelleted from low passage viral cultures on all patients. Cells were then washed twice
with PBS and resuspended in 5 ml1ysis buffer (10 mM Tris , 400 mM NaCl, 2 mM EDT A
pH 8.2) to which was added 10% SDS to a 0.7% final concentration and 1.7 mg proteinase
K. Tne'lysed cells were incubated at 37 C overnight. Afer overnight incubation, DNA
was obtained following ths incubation by adding 1.6 ml NaCl , centrfuging for 15 min at
2500 rpm and adding 7 ml iso-propanol to the supernatant. The DNA was pelleted by
centrifugation at 3500 rpm for 20 min, washed with 70% ethanol and stored at - C unti
PCR was performed.
3. PCR: Approximately 200 ng of genomic DNA from each of the eight cultures
described above were used to amplify a 2.6 kB product of HIV- l proviral sequence
containing the entire coding sequence for gp160. Reaction conditions were 2.5mM MgC1
200 uM of each dNTP, 50 mM KC1 , 10 mM Tris-HC1 , pH 8.3 (GeneAmp PCR Buffer II -
Perkin Elmer), IOpM of primers MNA and MN13 and 2.5U ArpliTaq (Perkin Elmer).
PCR reactions were intialy melted for 3 min at 94 C, followed by addition of ArpliTaq
during an 87 C hold. The cycling program consisted of 30 cycles of the following: 
denaturation at 94 , 1.5 min annealing at 60 C and 3 min extension at 72 C, followed by
a final 10 min extension at 72 C. In a nested amplification of a smaller fragment of the env
gene, the fIrst PCR reaction was spun though CL-4B sepharose. Ten percent of the first
reaction was used as template in a second amplification to yield a 964 bp fragment of env
containing Vl- V3. This was amplifIed using primers designated 209- and 218. Env clones
were used as templates to generate 32p internally labeled PCR products using dCTP in
the dNTP mix according to the methods of De1war, et al (2). PCR conditions using
primers 209 and 218 were the same as those for MNA and MN13 described below except
for a MgC1z concentration of 4rn instead of 2.5rn. Cycling conditions were the same
except for the absence of a hot star and an annealing temperature of 55 C instead of 60
D. Divergence analysis of patient provirs from mv -III using heterodup1ex fonnation:
1. Heterodu 1ex fonnation: Heteroduplexes were fonned between the labeled and
unlabeled PCR products as described by De1war, et al (2). Briefly, PCR products were
combined in a ratio of 1:100 1abeled:unlabe1ed in l00rn NaCl, IOrn Tris-HCl (ph 7.
and 2 rn EDTA in a total volume of IOu!. This mixture was heated at 94 C for 2 min.
and then rapidly cooled on ice.
2. Gel electro horesis: DNA fragments were separated in a 5% polyacrylamde gel
(30:0.8 acry1amde: Bis) in TBE buffer (0.088M trs-borate , 0.089M boric acid, 0.002 M
EDTA, pH 7.0) at 30rn for 12 hr. The gel was then dried for 1 hr at 80 C and exposeci to
radiographic fim.
E. Vaccinia Vector Constrction:
1. Li atin env ene into CR3 In Vitro Approxiately 30% of the PCR
products were electrophoresed on a 0.8% agarose gel and the 2.6kB fragment from each
was excised and cleaned with the gel purification kit E1uquick (Schleicher & Schuell). The
addition of dA TP to the 3' ends of PCR products cared out by Taq polymerase was
utiizd to ligate these products into a eukarotic expression vector, pCR3 (InVitrogen)
which possesses overhanging dTTPs on its 5' ends. Fifty ng of pCR3 was ligated with
approxiately 120 ng of the gel purified PCR product to achieve an insert:vector ratio of
approximately 4:1 using lu1 T4DNA ligase (InVitrogen) in a ligation reaction of lOul tota
volume. The ligation reaction was incubated at 16 C for 3 hrs. Two u1 of the ligation
reaction was used to transform 50u1 competent TOP 1 OF' cells (InVitrogen) in the following
marmer: 50ul of TOPI0F' cells previously stored at - C were thawed on ice and mied
with 2 ul of the ligation reaction. This was incubated for 20 min on ice and then heat
shocked at 42 C for exactly 45 sec. Thee hundred and fift ul of LB media were added
and this was incubated on ice for 2 min., One hundred ul of ths was plated onto LB agar
plates containing l00uglrn carbenicilin (SIGMA) and incubated overnight at 37
2. Pre aration of lasmid DNA for screenin Ten colonies were selected for
screening from ligations involving the following env s: Patient VI-06 at 6 months of ge;
patie:1t VI-08 at 20 days and 6 months of age; Patient VI-05 at 2 months and 6 months of
age. Twenty colonies were selected and screened from ligations involving env s from
ient VI- II at 1 month and 3 months of age and patient VI-6 at 1 day of age. These
colonies were inoculated into 3 ml of LB containing 100 uglrn carbeniciln and grown at
C over night. Plasmid DNA was isolated using an acid-phenol rnniprep to render the
DNA clean enough for sequencing. Acid phenol is used in place of phenol chlorofonn in an
alaline lysis procedure afer precipitation of cell debris and SDS with potassium acetate.
The aqueous layer is furter extracted with chloroformisoamyl alcohol (24: 1, vo1:vo1)
followed by conventional ethanol precipitation.
3. Screenin of 1asmids: a. Restrction Digests: approxiately 1 ug of DNA
from these preps was used to detennne whether the plasmid contained ar env insert in 
ul restrction digests using 1 u1 EcoRI which cleaves on both sides of the cloning site of
pCR3. h. Sequencing: 1. To detenne orientation: al plasmids contaning the 2.6kB
insert were sequenced to detennne their orientation withn pCR3 in the following maner:
Approximately 1 ug of DNA was denatured using 200 rn NaOH and .2 rn EDT A in
the presence of 70ng of either T7 or SP6 primer (In Vitrogen). The denatured DNA was
precipitated with 200 mM sodium aceta pH 4.5 and 3 vol ethanol, washed with 70%
ethanol and dred for 2 min. in a speedvac. The DNA pellet was resuspended and
sequenced according to the Sequenase 2.0 protocol (USB) using dA TP (NEN). 2.5 ul
of these reactions were analyzed on a vertcal polyacrylamde gel containing 6% acry1amde
and urea in TBE buffer using the Model S2 Sequencing Gel Electrophoresis Apparatus -
(Gibco BRL). Briefly, the sequencing reactions were heated for 2 min at 85 C and then
electrophoresed at 40mA for 1.5 hr. The gel was then dried for 1 hr at 80 C, exposed to
radiographic fim for approximately 12 hr., developed and read. 2. CI epitope analysis:
Al of the clones obtained from patients VI-06 and VI-08 were sequenced with primers
MNA , 210 , 209 , 212 , 214 and 215. These are regions within env that contain sequences
published as CT epitopes restrcted by HLA-A2 (8, 87). Translation of these nucleotide
sequences was perfonned using Mac Vector (Eastman Kodak).
4. Grou of env clones: PlasITlids containing the env iTsert from each patient at
each time point were digested with StuI (NEB), Ava! (NEB), BamI (Promega), KpnI
(Promega), BglI (Promega) and HindIn (Promega). The presence of distinct groups of
clones could be observed withn env clones derived from each patient at each tie point by
the appearance of distinct restrction digest patterns. Each clone was categoried into one
of the groups represented by a parcular restrction digest pattern. Based upon these
restrction patterns, the most commonly represented env clone was chosen to be subcloned.
5. Subcloning of env genes into pAbT4587 A: a. Competent E. coli DH5a: E. coli
strain DH5a were made competent using a conventional calcium chloride protocol. 
Creating XhoI site in pAbT4587 (Therion): The pAbT4587 plasmid from Therion was
modified in order to create appropriate restrction sites for diectional subc10ning of the env
genes ligated into pCR3. The previously existing EcoRI site was destroyed by EcoRI
digestion of 1 ug ofpAbT4587 followed by incubation with 1 u1 Klenow fragment and 125
uM each dNTP at room temperatue for 30 min. The plasmid DNA was then extrcted
once with phenol chlorofonn and ethanol precipitated and used in a ligation reaction with 
ug of non-phosphorylated XhoI linker (New England Bio1abs) and lul of T4 DNA ligase
(Pro mega). The ligation reaction was alowed to proceed at room temperature for 1 hr.
Half the ligation reaction was used to transfonn 100 u1 competent E. coli strain DH5a and
colonies were grown overnight at 37 C on LB plates containig loouglrn carbenicilin.
. - 
Ten colonies were selected and minicu1tures were set up as previously described. Plasmid
DNA was isolated from these cultures using a conventional alaline lysis mini prep
protocol. Approximately 1 ug of DNA was used to screen for the presence of the XhoI site
by a double restrction digest using 1 u1 XhoI and 1 u1 HindU!. The modified plasmid,
designated pAbT4587 A, was amplified in a 250 rn culture of LB/carbenicilin and
maxiprepped and purified using the Qiagen maxi prep kit. c. Ligation of selected env genes
into pAbT4587 A: One env gene was selected from each set of clones from each patient at
each tie point as previously described for a total of 8 env cloneso In each case the env
gene was in the corrct orientation for expression by the CM promoter within pCR3.
Each env gene was excised from the pCR3 backbone using Bar and XhoI which are
located within the pCR3 cloning site, 5' and 3' of the env gene , respectively. The 2.6kB
BarI-XhoI fragment was gel purified using E1uquick (Schleicher & Schuell) and ligated
into the Bar-XhoI fragment of pAbT4587 A at an insert:vector ratio of 4: 1 as previously
described. Competent E. coli strain DH5a were transfonned and colonies selected and
minicu1tured as previously described. Plasmid DNA was prepared from 6 separate
colonies derived from each ligation using a conventional alaline lysis protocol and
screened for the presence of the re1event insert by a double restrction digest using Bam
and XhoI. One plasmid from each ligation positive for the 2.6kB insert was amplified in
250rn LB/carnicilin and maxprepped with the Qiagen maxprep kit. d. Analysis of
subc10ned env s using HTA: p 1abe1ed-PCR products of 964 bp spaning VI-V3 as
described above were generated from the env genes ligated in the pCR3 backbone selected
for subc1oning. These were then used as probe against PCR products derived from their
subc10nes (ligated into pAbT4587A) as previously described. A second probe , the VI-
PCR product of pNL- , was also used to probe the subc10ned envelope genes.
Table 6. Patient derived env clone designations.
Patient clone na clone na clone na clone name at
st time point st time point 2nd time 2nd time point
in pCR3 in pAbT4587 A point in pAbT4587 A
in pCR3
VI - pCAR- pTAR- pCAR-
VI- pCHE- pTHE- pCHE- pTH-
VI- pCJA-20D pTJA-20D pCJA- pTJA-
VI- pCRO- pTRO-IM pCRO- pTR0-3M
ND: not done due to lack of stab1ity of env gene from ths time point in ths plasmid
Env genes were amplified by PCR and cloned into pCR3 (InVitrogen) and have the
designation "pC" preceding the clone name. One representative env clone from each set 
clones derived from each time point from each patient was chosen due to its predomiance
(detennned by restrction digest). The env gene from ths clone was subcloned into the
pAbT4587 A plasmid and the resulting subclone has the designation of "pT' preceding the
clone name.
6. Transient Ex ression Anal sis a. Infection of RK- 13 cells with vaccina:
Mono1ayers ofRK- 13 cells (ATCC # CCL37) grown in DMEM, 10% FCS in 6-cm dishes
were infected with wild type vaccinia virs vAbT33 (Therion Biologics) at an MOI of 1 in
DMEM, 2% FCS. These were incubated at 37 C, 5% CO for 45 min. b. Transfection of
vaccinia infected RK"' 13 cells: At the end of ths incubation, the vaccina-infected cells
were . transfected with 20 ug of each env clone described above using a conventional
calcium phosphate trsfection method (88) and incubated at 37 C, 5% CO for 16 hrs. c.
Cell staning: Following the 16 hr incubation, cells were fixed in formaldehyde and
incubated for 1 hr at 37 C with a serum pool from rabbits imunied with env protein
from HIV- l nm and HIV- l SF- which was diluted 1:500 in phosphate buffered saline (PBS)
and 50% normal goat serum. Cells were then washed and incubated with :200 goat anti-
rabbit IgG (H&L) (Perr & Kikegaad Laboratories) conjugated to alaline phosphatase
for the same amount of time. Cells were then washed and 1 rn of BCIPINT
substrate/developer (P & L Laboratories) was added. The reaction was allowed to proceed
for approximately 5 minutes and was stopped by the addition of 2 ml PBS. Expression of
env was detennned by th\'o presence of blue-stained cells.
. -
7. Recombinant vat.CInIa eneration: a. In Vitro recombination: In ',itro
recombination and recombinant vaccinia generation were perfonned according to the
methods detai1ec by Maza et. al. (88). The infection and transfection of RK- 13 cells
used to achieve recombiration between wild type vaccinia and the env clones was as
described above with the exception t at the cells are incubated for 48hr instead of 16hr. b.
Selection ofre ombinant8: \Vhen the cells demonstrated 100% CPE at 48 hr, the medium
was removed and the cells were scraped into lrn Tris-HC1, pH 9.0 and freeze/thawed 3
times to release virus. Ten-fold serial dilutions were prepared from the IV-generated
virus. 10- to 10- dilutions were plated on confluent mono1ayers of RK- 13 cells in 6-cm
dishes in media conditions described above and allowed to adsorb for 30 min. Following
adsorption a 0.6% agarose-DMEM-5%FCS overlay was added. After a 48 hr incubaton at
C, 5% CO , another overlay was added containing 0.4 mglrn B1uogal (SIGMA). This
was incubated for another 48 hr. at which tie 8 white plaques were selected from each
IVR and stored at - e. Confluent mono layers of RK-13 cells in 6-cm dishes were
infected with 5u1 and 10u1 of one of each set of plaque isolates for furter purification.
Agarose overlays were added as previously described. If no blue plaques were present at
ths second step, vaccinia recombinants were considered to be pure from the first plaque
isolate. If blue plaques appeared, white plaques were again selected from the second round
isolates and underwent a thd round of purification to ensure purity. Pure plaques were
then amplified on confluent RK- 13 cell mono1ayers in 6-cm dishes and virs was obtained
48 hr after infection by the freeze-thaw method described above.
8. Anal sis of ex ression usin a radioirnuno reci itation assa Confluent
mono1ayers of CV - 1 (A TCC# CCL 70) cells in 6-cm dishes were infected with 400 ul of
crude virus prep from each IVR as described above and siru1taneolls1y labeled with 100
uCi S-met; S-cys (NEN) in methonine and cysteine free DME, 4% FCS for 16 hr at
C, 5% CO , Cells were then scraped into RIA buffer containing 1 % (v/v) Triton X-
100 , 1 % (v/v) sodium deoxycholate, 0. 1 % (w/v) SDS, 10 rn Tris-HC1 (ph 7.5), 0.25M
NaCl and 5rn EDTA (88). Cell 1ysates were split and incubated for 2 hr at room
temperature with pooled sera diluted 1:200 from ID positive or HIV negative individuals.
Imune complexes were then precipitated with protein A-sepharose for 90mi at room
temperature. The beads were washed several times in RIP A buffer and the imune
complexes were removed from the beads through a 10 min incubation at lOooe. An equal
volume of 2X Laerni sample buffer was added to each irnunoprecipitate and loaded into
the wells of a denaturing 6% Laerni polyacrylamde geL The gel was run at 150 rn for
4 hr, fixed, enhanced with Amplify (Amersham), dred at 80 C for 2hr and exposed to
radiographic fim.
Amplification. purification and titration of recombinant vaccinia virus
amplication: confluent mono1ayers of RK - 13 cells in 6-cm dishes were infected with 400u1
of crude virs preparation and incubated unti1100% CPE were obtaed (approximately 48
hr). These cells were scraped into lrn Tris-HCl, pH 9.0 and freeze-thawed thee times.
All of ths crude virs preparation was used to infect a confluent monolayer of RK- 13 cells
grown in a T- 175 tissue culture flask (approximately 15 x 10 cells) and incubated at 3T)
5% CO until 100% CPE was demonstrated. Cells were scraped into 5rn Tris-HC1 and
virus released as described above. b. Purification on sucrose cushion: virs was purified
according to the method of Mazar et al (88). Briefly, the 5 rn of amplied virus was
layered on 15 rn of 36% (w/v) sucrose in rn Tris-HC1, pH 9. , in a 30-rn Beckman
ultracentrfuge tube for the SW28 rotor. These were then centrfuged for 1 hr at 20,000
rpm at 4 C to pellet the virs. The viral pellet was resuspended in 1 ml of 1 rn Tris-HC1,
pH 9. c.Titering of purified virus: virs was titered according to the me hod of Mazar
al. (88) with slight modification. Briefly, confluent mono1ayers of CV- l cells in 6-well
plates were infected in duplicate with 0.4 rn of lO-fo1d serial dilutions of purified virus
over a range of 10-6 through 10- 11 dilutions. The cells were incubated for 48 hr at 37 C, 5%
, Media was removed and 0; 1 % (w/v) crystal violet in 20% (v/v) ethanol was added
for approximately 7 min. The mono1ayers were then rinsed with water and the plaques
were counted after the plates were dr.
F. Precursor Frequency Detennnation using Limiting Dilution Analysis:
In vitro stiulation and LDA were performed using the method by Koup et al (32)with
modification.
1. Vaccinia Vectors : Vaccinia vectors vac (non-recombinant NYCBH vaccina) a.'1d
vv271 which expresses env of the ID- II strain derived from the BRIO molecular
clone (designated as II in the Results section) were provided by Therion Biologics.
Table 6 summarzes the vac constrcts derived from clinical isolates.
2. Feeder cells: PBMC were isolated using Ficoll from freshly drawn heparzed
blood from healthy seronegative donors and stiulated for 48 hrs with 5U/mI IL-2 in
RPMI with 10% FCS. They were then iradiated with 3500R and resuspended in RPMl
containing 15% FCS , 30U/mI IL-2 and 2.5 uIlmI OKT3 at a concentration of either 5 x 
cells/mI or 2.5 x 10 cells/mJ to act as feeders for PBMC derived from infants at very early
time points or later time points respectively.
3. Effector cells: PBMC were isolated from freshly drawn heparnied blood from
ID- positive infants quantitate.d and cryopres rved in 10% DMSO, RPMI 10% FCS
using a cell freezing program (KRYO 10 series) and stored in liquid nitrogen as par of a
patient PBMC repository. These were then thawed rapidly, washed and resuspended at
160 000 cellslrrJ in RPMI containing 15% FCS , 30U/ml IL-2 and 2.5 uIlmI OKT3. One
hundred ul of each serial dilution of these cells were then plated into 24 wells of a 96-well
bottom plate , ranging from 16,000 cells/well to 500 cells/well. PBMC from every time
point examined for each patient were stimulated with the same donor cells to lessen
interassay varabilty.
4. In vitro non-s ecific stimulatioq: One hundred u1 of iradiated PBMC feeders
were added to each well of effectors and incubated for 5-7 days (until visible cell growth
had occurred) at 37 , 5% CO , Media were exchanged every fourth day.
5. Target cells: Autologous B- lymphob1astoid cell lines were established from each
patient by infection ofPBMC with supernatat from the EBV-producing cell lie B95.8 in
RPMI, 15% FCS 10% B95.8 supernatant and 2 uglrn cyc1osporin A. Transformed B
1ymphob1astoid cells were subsequently grown and maintained in RPMI, 15% FCS.
Table 7. Recombinant vaccinia vectors derived from patient env sequences
Patnt st time point 2nd time point
VI- vvAR-
VI- vvHE- vvHE-
VI- vvJA-20D vvJA-
VI- vvRO- vvRO-
Recombinant vaccina vectors expressing env genes of the viral isolates cultured from
patients VI - , VI - , VI -08 and VI - 11 were generated though in vitro recombination
between the env subc10nes in pAbT4587A and wild type vaccinia as described in the
Materials and Methods section.
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6. C otoxici Assa : a. Effectors: Effector cells were divided by the number of
targets being assayed into 96-well U-bottom plates. RPMI with 15% FCS was added to
each well to bring the tota volume to 100 ul. b. Targets: 1. Vaccinia-'inected tagets:
Autologous B-LCLs were infected with vv at an MOI of 5: 1 for 16 hr at 37 C, 5% CO
RPMI, 15% FCS with an intial 60 rn incubation at a concentration of 3 x 10 cells/mI
with gentle agitation followed by 15hr of incubation at 1 -x 10 cells/mI. They were then
washed and radio1abe1ed with loouCiNa Cr (NEN)/1 x 10 cells at a concentration of 3 x
cells/rn in RPMI, 15 for 1 hr at 370C with gentle agitation. Following
incOIporation of label , the targets were washed twice and resuspended in RPMI, 15% FCS
at a concentration of 1 x leY cells/mI. One hundred u1 of these were then added to the wells
containing effector cells. Twenty four wells were reserved for each taget into which only
target cells and media were mixed (in the absence of effector cells) and were designated as
spontaneous release wells. Fifty u1 of each target was pipetted into 6 replicate tubes and
were used to measure average maal chromium release of the targets. The plates
containing targets and effectors were centrfuged at 1500 rpm for 3 min. and incubated for
7 hr at 37 5% CO , 2. Peptide-pulsed targets: Autologous B LCL were coat d with
peptide by incubation at 37 C for 1.5 hr with 200 ugimI peptide in RPMI, 20% FCS and
simultaneously radio1abe1ed with 100 uCi Na Cr/1 x 10 cells at a cell concentration of 3 x
c::1Js/ml. The targets were then handled as described above. c. Peptides: Peptides
1923 and 1930 were received from the AIS Research and Reference Reagent Progra..n
(AnaSpec). Peptide V3- 1 was prepared at UNC peptide facility. Lyophy1ized peptide
was resuspended in 10% DMSO in PBS to a concentration of 2 mg/ml. Peptide sequences
are follows: 1923: VPVWKEA 1TFCASDAKA Y, 1930:
WDQSLKPCVKLTPLCVTNC and 291: SVEINCTRPNNNTRKSI. d. Assay readout:
The plates containing targets and effectors were centrfuged as above at the end of 7 hrs and
100u1 of supernatant from each well was collected and radioactively quantitated in a
Beckman gam counter. e. Calculatons: Percent lysis was calculated for each well
using the formula 100 x ((test cpm - spontaeous cpm)/(maximal cpm - spontaeous cpm))
using a MacIntosh Excel Spreedsheet created by Dr. Spyros Kalars, Massachusettes
General Hospital. The cut-off for a positive response was above 10-20% lysis depending
upon the amount of background withn the assay. Simple liear regression analysis was
performed by using the least mean squared method. Precursor cell frequency was
calculated by solving the equation of the best fit line in which the negative log frction 
the nonresponding wells equaled one (fraction of nonresponding wells = 037). Ninety-
five percent confidence lits were calculated based upon the tre mean value of the
dependent varable, PBMC per well.. Split-well analysis was also performed and precursor
frequencies of Cf recognizing multiple targets were determed using ths worksheet.
Wells positive for lysis of more than one env-expressing target were considered negative 
they were also positive for lysis of wild-ty vaccina virus-expressing targets. The
number of negative responses was detennned using ths criteria for multiple env
expressing taget recognition and entered into the spreedsheet to obtan the precursor
frequency. The percentage of pCT cross-reactive with each combination of env-
. -
expressing targets was then calculated based upon the precursor frequencies of per able
to recognize single env-expressing targets and pCTL able to recognie more than one env-
expressing target.
G. Antibody-Dependent Cellular Cytotoxicity Assay:
ADCC antibody assays were performed according to the method of Koup et al (52)
1. Vaccinia Vectors: The recombinant vaccina vectors used were those described
above.
2. Plasma: Plasma derived from HIV - 1 positive infants at time points ranging from
2 months to 2 years of age was heat-inactivated at 56 C for 45 minutes. Plasma was then
serially diuted with RPMI, 15% FCS using half log dilutions from 10- to 10- . Plasma
from ID- infected individuals with hemophilia was pooled, heat-inactivated and used as
a positive control.
3. Effectors: PBMC were isolated from freshly drawn hepared blood from
healthy HIV - 1 seronegative donors and resuspended to a concentration of 2.5 x 10
cells/well.
4. Tar ets: A B-LCL line designated MC-LCL was used in al assays at a
concentrtion of 1 x 10 cells/well. These were infected with vaccina and labeled with
, as previously described.
5. C assa : The ADCC assay was a modification of that reported by Konp et
al. Twenty u1 of diluted plasma was aliquotted in trplicate into wells of a 96-well U-
bottom plate for each plasma sample. A trplicate set of wells designated as "spontaneous
release" received 20 u1 of plasma at the lowest dilution. Ninety u1 of tagets were added to
each well and incubated for 30 min at 37 C, 5% CO , Following ths incubation, 90 u1 of
- .
effectors were added to each well except for those designated as spontaneous release wells.
The plates were centrfuged at 1500 rpm for 3 min and incubated at 37 C, 5% CO for 8 hr.
An additional 96-well plate was also set up in trplicate to measure chromium release in the
absence of plasma in which 20 u1 of RPMI 15% FCS was added in place of plasma with
the same effector and taget cell input. Forty five u1 of each of the target cells were
collecteti Into 6tubes to measure average maximal chromium release. After 8 hr" the plates
were centrfuged as above and 1 00 u1 of supernatant were collected and counted in a
Becbnan gama counter.
6. Calculations: Percent lysis for each plasma dilution was detemlned by the
formula: 100 x ((test cpm - spontaneous cpm)/(maxmal cpm - spontaneous cpm)).
Percent ADCC cytotoxicity = percent lysis of tagets with plasma - percent lysis of tagets
in the absence of plasma. The antibody titer of the plasma was detennned by calculatig
the mean and standard deviation of ADC lysis of wild tye vac inected tagets at each
plasma dilution with each plasma sample tested. From these values, a cut-off value of two
standard deviations above the mean was established for each plasma dilution. The antibody
titer against env-expressing targets was then defmed as the highest plasma dilution which
stil gave an ADCC lysis value above the cut-off for that dilution.
CHAPTR m. RESULTS
A. Diversity of patient proviral DNA sequences from 
jo, Past studies had measured infant imune responses agaist HI - 1 with a III
based vector, 271, which was derived from II env. Genetic differences between ll env
and the autologous HI -1 env replicatig in vivo may explai the lack of detection of 
withn early infancy. Therefore, the amount of diversity from II was examned in each
of the patent's proviral DNA though heterodup1ex formation with pAbT4603. The PCR
product analyzed covers hypervarab1e regions VI-V3 withn the env gene. mV- MN and
HIV - 1 IDB differ by 8 % withn this region as detenned using best fit analysis in GCG 
Genetics Computer Froup s Wisconsin Sequence Analysis Package version 8. 1 using the
default program parameters. Figure 1 shows that the distance of migration of the
heteroduplexes formed between the patient proviral DNA and UIB env ar close to that of
MN env and mB env. This suggests that the amount of diversity of the patent isolate
sequences from ll within env is at least 8%. Furthermore, a comparson of llle relative
mobilties from the early and later time points from each individual probed with mB shows
little difference. Relative mobilties were obtained for the heteroduplexes by calculating the
average distance of migration from the wells of the gel of the heterodup1ex bands divided
by the distance of migration of the homodup1ex bands. Using till': formula by Delwar, et
al.(2), DNA distance
;: -
In ((mobility- 045)/1. 14)/13.6, derived by plotting Ie1ative
heterodup1ex mobilty agaist percent DNA distance, Lhe diversity within ths region ranged
from 4. 8 - 5.4% among the patient isolates (Figure 2).
Analysis of the heterodup1exes which formed between III env and patient proviral
env demonstrate differences in patient env heterogeneity at the two tie points examned
(figure 1). A greater extent of heterogeneity was observed within proviral env sequences at
1 day of age than at 6 months of age of patient VI-06. This was represented by the
formation of a multiple heterodup1exes. These heterodup1exes migrated closely suggesting
that they were closely related to one another. There appeared to be only one predomiant
env sequence at 6 months, represented by the formation of two heterodup1exes. Proviral
env from patient VI-05 developed greater heterogeneity by 6 months of age. At 2 months
of age there appeared to be only one predominant env sequence. Env sequences of patient
VI-08 did not become more heterogeneous from 20 days of age to 6 months. At each 
point there appeared to be only one predominant sequence. However, comparson of these
two time points demonstrated an env sequence which is more closely related to nff at 20
days of age. Proviral sequences of patient VI- II appeared to be identical at each tie point
although clones derived from these samples differed.
Figure 1. Heteroduplexes fonned between patient proviral
DNA and IIB env
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Figure 1. Heterodup1exes fonned between patient proviral DNA and II env
Env fragments were amplified by PCR from genomic DNA extrted from PBMC infected
with patients ID- l isolates and from a plasmid contaning BHlO (II) env (pAbT4603).
The PCR fragment is a 946 bp product which contains sequences withn env which span
VI to V3. The PCR product of pAbT4603 was internally radiolabeled during the PCR and
combined with the PCR products of the patient s proviral templates to fonn heterodup1exes
as described in the Materials and Methods section. Lanes 1-3 are clones of known
- -
sequence probed with pAbT4603. Lane 1 is a PCR product of pNL-3 which contains the
LA V strain of ID -1 (clade B). Lane 2 is a PCR product of env of the MN strain of ID-
(the prototypical clade B strain of ID - 1) using plasmid pT2020 as template and lane 3 is a
PCR product of env from an env clone derived from patient VI-08 (pJA- 1D). Lane 4-
are PCR products amplified from patient proviral DNA (VI-06 is AR- ID and AR- , VI-
05 is HE-2M and HE- , VI-08 is JA-20D and JA-6M and VI- II is RO- IM and RO-3M).
Lane 12 is a negative control of probe alone.
Figure 2. Percent genetic distance of patient proviral DNA from 
NL43
pJA-
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HE-2M
HE-
JA-20D
JA-
RO-
RO-
Relative mobilties of the heterodup1exes depicted in figure 4 were obtained by measuring
the average migration of the heterodup1exes from the wells of the gel divided by the
distance of migration of the homodup1exes. Percent diversity was detemlned using the
formula DNA distance = -In((mobilty- 0.045)/1.14)/13.6 (2).
B. Recombinant vaccinia virs constrction
1. Amplification and cloning of the env gene using PCR from infant isolates: The
env gene was successfully amplified and cloned using primers which anealed upstream
and downstream of the gene (figure 3). These PCR products were subsequently ligated
into the pCR3 backbone from which 60 env clones were derived and categorized (Table 8)
based upon restrction digest patterns. One env clone which was predominant was selected
for each patient and subc10ned into pAbT4587A. The selected clones are presented in tale
8. Each env gene was then subcloned into pAbT4587 A and used to generate recombinant
vaccinia virus. The env gene from pCAR-6M could not be subc10ned because of lack of
stabilty of ths gene in pAbT4587 A. Therefore, a total of 7 env subc10nes were generated.
Clones and subclones of patient env sequences were analyzed though heteroduplex
fonnation to ensure identity of the env genes cloned. The derivation of al env genes
subcloned into pAbT4587 A was verified using identical env genes ligated into the pCR3
backbone as probe (figure 4). Absence of contamnating env sequences was shown by the
lack of heteroduplex fonnation between these env fragments. Because pNU-3 was used
.. . - . . -
frequently as h positive PCR control, it was also used as a probe to make sure that none 
the cloned env sequences were in fact pNU-3. The fonnation of heterodup1exes of
varing mobilty between pNU-3 and these env fragments further verifred lack of
contamnation and demonstrated that each of the env clones was unique to one another.
2. Ex ression anal sis of subcloned env enes: Patient env genes in pAbT4587 A
were analyzed for their abilty to encode env protein. This was accomplished through
transfection of the env subclones into vaccinia-infected cells. Expression of the env gene is
driven by the 40K vaccinia promoter which is activated by the presence of wild type
vaccinia within the transfected cell. Incubation of these cells with ID - 1 env-specific
rabbit sera followed by a phosphatase-labeled goat anti-rabbit second antibody
"'-
demonstrated the presence of env protein by the appearance of blue-staned cells (figure 5).
Cell surface membrae staining was the predominant pattern. Al of the subcloned env
demonstrated the abilty to make env protein.
3. Expression ana1ysis of recombinant vaccinia vectors derived from patient env
genes: Recombinant vaccina virus was derived from the seven env clones described
above. Prior to amplification of these vectors, their abilty to encode env protein was
examned by irunoprecipitation (figure 6). All of the vectors were shown to encode for
gp160 and its cleavage product, gp120 (gp1, a second cleavage product migrted beyond
the detectable limit of the gel).
C. Precursor Frequency of CTL recognizing heterologous and autologous env-expressing
targets of patients VI-06, VI-05, VI-08 and VI-
CTL precursor frequencies were measured in all of the patients at ages at which we
had been unable to detect II-env-specific Cf responses. Although II-env-specific
CT were not present, CT precursors from 3 out of 4 of these patients recognized env
from autologous viral isolates at frequencies within a range (39- 130 pCTU10 PBMC)
(table 10) of those reported against laboratory strains of HIV- l in older children (67),
Patient VI- , a patient who had previously been shown to have pCTL against the IIIB gag
gene product within cord blood (68), possessed low numbers of pCT in cord blood
against the env gene product cloned from virs present at 1 day of age (figure 7 A).
Although the frequency of pCTL against autologous env protein is not statistically higher
than background, previous detection of pCf in cord blood from this patient supports the
possibilty that the higher frequency of pCTL detected against ths env product is real. CTL
precursors from patient VI-08 at 6 months of age were highest against the env gene product
cloned from virus present at 20 days of age (figure 9A). A lower frequency of pCTL was
detected from ths patient at ths tie point against the env gene product cloned from virus
present at 6 months of age. This lower frequency was not statisticaly higher than
background but was high enough to suggest possible recognition of this env gene product
as well. At 3 and 7 months of age, pCI from patient VI- II recognized both env gene
products cloned from virus present at 1 month and 3 months of age (figure lOA and B).
No pCf were detected in the cord blood of patient VI-05 against either autologous env
gene products or II (figure 8A).
Al four patients demonstrated pCf able to recognze II and au ologous env
gene products by at least 12 months of age. Patient VI-06 demonstrated group-specific
CTL responses as early as 6 months of age (figure 7B). Group-specific Cf responses at
this age are considered to be unusually early as II responsiveness , measured previously
in our laboratory and in this study, was not detected in the other 3 patients unti
approximately 12 months of age. CT precursors from patient VI-05 at 12 months of age
recognized both the II env and the env gene product cloned from virs present at 2
months of age (figure 8B). Curiously, pCf from ths patient at 12 months of age were
not able to recognize the env gene product cloned from virus present at 6 months of age.
By 19 months of age, pCTL from patient VI-08 recognized the IliB env and the env gene
products cloned from virus present at 20 days and 6 months of age (figure 9B).
comparson to the level of recognition at 6 months of age of the env gene product cloned
from virus present at 6 months of age, the frequency of pCT recognizing ths env protein
by 19 months of age was significantly higher than background. By 12 months of age,
patient VI- l1 possessed pCTL able to recognize the nIB env gene product as well as both
autologous env gene products (figure IOC).
Figure 3. Env PCR products derived from patient provirus
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Figure 3. Env PCR products derived from patient provirs.
Genomic DNA from PBMC infected with viral supernatant from HIV - 1 isolates from
patients VI-06, VI-05, VI-08 and VI- ll described in tale 2 was used as template to
amplify the entir coding region of env by PCR as described in the Materials and Methods
section. Molecular weight standards ar in lane 1. Lanes 2-9 ar PCR products derived
from patient proviral DNA using primers l\A and l\13 described in table 4.
Table 8: Grouping of env clones of patient isolates withn pCR3 based upon restrction
digests with StuI, A val BarI, KpnI, BglI and HindUI:
GrouD Patient a Correct* Reverse Percent of cIonesI
VT ()i' 1 rI '77.
06 ID-
06- ID- 13 1- 15 1-20 1- 11 1-
06- ID-
06-6M- VI-06 6 IDO 1 2-72-82- 22-32-42-
066M-
05-2M- VI-05 2 IDO 4 3-5 3-7 3-8 3-
05-2M-
05-6M- VI-05 6 IDO 2 4-5 4-8 4- 4-4 4- I ()
08-20D- VI-08 20d 5-4
08-20D-B
08- 20D- 2 5-3 5-8 5-9 5-
08-6M- VI-08 6 IDO
08-6M- 26-36-46-76-86-96-
II- IM- VI- 1 IDO
II- IM- 10 7-117- 27-57-77-
I1- 1M-
11-3M- VI- II 3 IDO
11-3M- 11.8- 14. 16.
Env genes amplified by PCR from provirs of patients VI- , VI-05, VI-08 and VI- II at
the time points indicated in table 2 were ligated into pCR3 (In Vitrogen) and digested with
StuI , A val, BamHI, KpnI, BglI and HindUL One to four distinct patterns of restrction
digests were obtained from each set of clones derived from virus from each patient at a
single time point which were designated as groups A , B , C and D. Individual env clones
were categorized into each group on the basis of their restrction digest patterns. The group
containing the largest number of clones was considered to be the predominant group and
one clone was then chosen from each predominant group for subcloning.
* Based upon orientation of gene relative to control of CMV promoter of pCR3
:j Percent of clones from the total number derived from one patient at one tie point which
fell within a parcular group
Table 9: Env clones selected to be subcloned into pAbT4587 A:
Patient, age clone new designation
VI-06, 1 day p 1- pCAR-
VI-06, 6 months p2- pCAR-
VI-05, 2 months p3- pCHE-
VI-05, 6 months p4- pCHE-
VI-08, 20 days p5- pCJA-20D
VI-08, 6 months p6- pCJA-
VI- ll, 1 month p7- pCRO-
VI- l1, 3 months p8- pCRO-
Predominant env clones were chosen from the clones presented in table 7 as described in
the legend for table 7 and in the Materials and Methods section. The env gene from these
clones were then subc10ned into pAbT4587 A as described in the Materials and Methods
section.
Figure 4. Heteroduplex analysis of cloned and subcloned env genes
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Figure 4. Heterodup1ex analysis of cloned and subcloned env genes.
Env fragments were amplified by PCR from env clones withn the pCR3 and pAbT4587 A
backbones described in tables 7 and 8 and from pNU-3. The PCR fragment is a 946 bp
product which contains sequences within env which span VI to V3. The PCR product of
env clones within pCR3 and pNU-3 were internally radio1abe1ed durng the PCR. The
PCR products of env clones withn pCR3 were combined with the PCR products of the
identical env subclones withn pAbT4587 A to form heterodup1exes as described in the
Materials and Methods section. The rao1abe1ed PCR product of pNU-3 was also
combined with PCR products of the env clones withn pAbT4587 A to form
heterodup1exes. Lanes 1-7 are subc10ned env genes probed with identical genes ligated
into pCR3. Lanes 8- 14 ar subcloned env genes probed with pNL4-3. Lanes 15-22 ar
negative controls containing radio1abe1ed PCR products alone.
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Figure 5, Cell surace stang of cells transfected with env plasmids
Figure 5. Cell surface staining of cells transfected with env p1asmids.
RK- 13 cells were infected with wild-type vaccinia virs and transfected with env gene-
containing clones in the pAbT4587 A or, in the case of pAbT4603, pAbT4587 backbone as
described in the Materials and Methods section. These cells were then incubated with sera
from HIV - 1 immunized rabbits. Env expression was detected by purple staning resulting
from incubation of these cells with a secondar goat-anti-rabbit antibody conjugated to
alalne phosphatase and treated with appropriate substrate. P1asmids used in transfection:
, mock. B pAbT4603. C, pTAR- ID. D, pTHE-2M. E, pTHE-6M. F, pTJA..20D. G,
pTJA-6M. H, pTRO- IM and I, pTRO-3M.
Figure 6. Immunoprecipitation of CV -1 celllysates infected with env-
recombinant vaccinia vectors
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Figure 6. Irnunoprecipitation of CV - 1 cell1ysates infected with env-recombinant vaccinia
vectors.
CV - 1 cells were infected with crude viral preparations of env-recombinant vaccinia viruses.
These cells were lysed with detergent and the 1ysates were incubated with either pooled sera
from HIV - 1 infected individuals with hemophilia or pooled sera from ID - 1 negative
individuals. Imune complexes were captured by protein A-sepharose and analyzed as
described in the Materials and Methods section. A: Cell1ysates irnunoprecipitated with
.1i
pooled sera from mV,. 1 inected individuals with hemophilia. Lanes 1-7 are vaccinia
recombinants of patient-derived env genes , lane 8 is a recombinant of env derived from
pAbT4603 generated as a positive control for vaccina vector constrction, lane 9 is wild
type NYCBH vaccina and lane 10 is an env recombinant vaccina vector from Therion
Biologics used as a positive control for irnunoprecipitaton. B: Lanes ar identical to
those in A but preciptated with pooled sera from ID- l negative individuals.
("..
Table 10. CTL precursor frequencies of patients VI-05, VI- , VI-08 and VI- lI over tie
against autologous env gene products and II env
3MO 6MO 7MO 12MO 19MO
VI- vac 34 (23-50) 0.5 (0.03-
IIB 13 (7-23) 153 (118-200)
vvAR- 64 (47-87) 197 (151-257)
VI- vac 18(11-30) 65 (48-89)
IIB 25 (16-39) 219 (169-284)
vvHE- 31 (21-47) 129 (99- 168)
vvHE- 55 (40-76)
VI- vac 50 (36-70) 19 (12-32)
IIB 50 (35-70) 201 (154-262)
vvJA-20D 130 (99- 170) 81 (60- 108)
vvJA- 80 (60- 107) 175 (135-229)
VI- vac 8 (4- 17) 3 (0. 10) 25 (16-39)
IIB 23 (14-36) 4 (I- II) . 62 (45-85)
vvRO- 136 (105- 177) 42 (29-60) 176 (136-228)
vvRO- 138 (107- 180) 70 (52-94) 74 (55-99)
Table 10. CTL precursor frequencies of patients VI-05, VI-06, VI-08 and VI- II over tie
against autologous env gene products and II env.
Precursor frequencies of Cf were measured by LDA at the tie points indicated as
described in materials and methods. Vaccina vectors used as targets were wild type
vaccinia: vac, II env expressing vaccinia: IT, env expressing vaccinia derived from an
ID- l viral isolate from patient VI-06 at 1 day of age: vvAR- , env expressing vaccinia
derived from an ID- l viral isolate from patient VI-05 at 2 months of age: vvHE-2M, env
expressing vaccinia derived from an HIV - 1 viral isolate from patient VI-05 at 6 months of
age: vvHE- , env expressing vaccina derived from an mV- l vir isolate from patient
VI-08 at 20 days of age: vvJA-20D , env expressing vaccinia derived from an HIV- l viral
isolate from patient VI-08 at 6 months of age: vvJA- , env expressing vaccina derived
from an mv - 1 viral isolate from patient VI- II at 1 month of age: vvRO- , and env
expressing vaccinia derived from an HIV - vir isolate from patent VI- II at 3 months of
age: vvRO-3M. Numbers in parentheses ar 95% confdence intervals for each frequency
value obtained using an MacIntosh Excel Spreedsheet kindly provided by Dr. Spyros
Kalars, Massachusetts General Hospital.
* Spontaneous release for this target was too high to detennne a precursor frequency value
Figure 7. Quantitation ofID- l env-specific CTL precurors in patient VI-06 in cord blood
(panel A) and 6 months of age (panel B)
:; 0.
a- .
. Q)
lL 0.
CORD BLOOD
000 000 000
------ . . . . . . . . . . . . .--------
8 -----------------------
--------------,.
cellsAvell
6 MONTHS
000 000 000
12,000 000
. . .  . . . . . .
000 15,000
""" , . -
cells/well
vac
- . .. .
IIB (0)
,---
---- wAR- 1 0 (30)
vac
. . . 
. IIIB (153)
---
-6----wAR-1D (197)
Figure 7. Quantitation ofID- l env-specific CT precursors in patient VI-06 in cord blood
(panel A) and 6 months of age (panel B).
Cf precursors were quantitated using limiting dilution assays followed by in vitro
stimulation of PBMC from CB and 6 months of age. HIV - 1 specific frequencies were
calculated as described in the Materials and Methods section. Cf precursor frequencies
were measured against wild tye vaccinia: vac II env expressing recombinant vaccina:
II and env expressing vaccinia derived from an HI - vir isolate from patient VI-06 at
1 day of age: vvAR- ID. Numbers in parantheses ar pCf values with vac background
subtracted. Spontaneous release was c: 30% for al tagets shown. The cut-off for a
positive response was 20% for the two assays.
Figure 8. Quantitation ofID- l env-specific CTL precursors in patient VI-05 in cord blood
(panel A) and 12 months of age (panel B).
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Figure 8. Quantitation of HIV - 1 env-specific CT precursors in patient VI-05 in cord blood
(panel A) and 12 months of age (panel B).
CI precursors were quantitated using limiting dilution assays followed by in vitro
stimulation of PBMC from CB and 12 months of age. HIV - 1 specific frequencies were
calculated as described in the Materials and Methods section. Cf precursor frequencies
were measured against wild tye vaccina: vac , UIB env expressing recombinant vaccina:
TIIB , env expressing vaccinia derived from an HIV- l viral isolate from patient VI-OS at 2
months of age: vvHE-2M, and env expressing vaccinia derived from an ID- l viral isolate
from patient VI-05 at 6 months of age: vvHE-6M. Numbers in parantheses are pCI
values with vac background subtracted. Spontaneous release was -c 35% for al tagets
shown except vvHE-2M in panel B which was 41 %. The cut-off for a positive response
was 10% for the assay depicted in panel A and 20% for the assay in panel B.
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Figure 9. Quantitation ofHIV- l en v-specific CTL precursors in patient VI-08 at 6 months
(panel A) and 19 months of age (panel B).
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Figure 9. Quantitation ofID- l env-specific Cf precursors in patient VI-08 at 6 months
(panel A) and 19 months of age (panel B).
Cf precursors were quantitated using liting dilution assays followed by in vitro
stimulation of PBMC from 6 months and 19 months of age. HIV - 1 specific frequencies
were calculated as described in the Materials and Methods section. Cf precursor
frequencies were measured against wild type vaccinia: vac, Il env expressing
recombinant vaccinia: HIB , env expressing vaccina derived from an HIV - 1 vir isolate
from patient VI-08 at 20 days of age: vvJA-20D, and env expressing vaccina derived from
an HIV- l viral isolate from patient VI-08 at 6 months of age: vvJA-6M. Numbers in
parantheses are pCTL values with vac background subtracted. Spontaneous release was
c:33% for all targets shown. The cut-off for a positive response was 30% for both assays.
Figure 10. Quantitation of HIV - 1 env-specific CI precursors in patient VI- ll at 3
months of age (panel A), 7 months of age (panel B) and 12 months of age (panel C).
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Figure 10. Quantitation of HIV - 1 env-specific CTL precurors in patient VI- II at 3 months
of age (panel A), 7 months of age (panel B) and 12 months of age (panel C).
CI precursors were quantitated using limiting dilution assays followed by in vitro
stimulation of PBMC from 3 months, 7 months and 12 months of age. HIV- l specific
frequencies were calculated as described in the Materials and Methods section.
precursor frequencies were measured agaist wild type vaccina: vac, UIB env expressing
recombinant vaccina: II env expressing vaccina derived from an HIV - 1 viral isolate
from patien VI- II at 1 month of age: vvRO- , and env expressing vaccinia derived from
an HIV- l vir isolate from patent VI- ll at 3 months of age: vvRO 3M. Numbers in
parantheses are pCf values with vac background subtracted. Spontaneous release was
.:35% for all targets shown except for targets expressing vvRO-3M in panel C which was
42%. The cut-off for a positive response was 10% for both assays depicted in panel A and
B and 15 % for the assay depicted in panel C.
D. Quantitation of cross-reactive and singly reactive pCT by split-well analysis:
The unique group-specificity of the CT response of patient VI-06 at six months of
age was derived from a pool of cross-reactive pCT (93% of al the env-specific pCI
detected), rather than two separate pools of pCTL in which one was autologous env-
specific and one II-specific. This is in diect contrast to that seen with the same patient in
the PBMC of cord blood in which there were only detetable pC to autologous env
sequences. Ths suggests that the pCT measured at 6 months of age were not derived
from those detected in cord blood but arose from a separate pool which expanded in vivo
between 0 and 6 months. The relationship between the detectale env-specific per
measured in these assays is depicted diagraratical1y in figure 11.
The pCrL detected within the PBMC of patient VI-05 at 12 months of age against
env from the patient's 2 month isolate and HIB env were derived from the different
pools. The majority of the pCT against the 2 month env were derived from a pool cross-
reactive with ilB (41 % of al env pCTL), whereas only 14% were specific only for the
autologous env. On the other hand, the II-specific per were equally represented by a
pool cross-reactive with autologous (41 %) and a pool recogniing only HIB (45%) (figure
12).
The per detected in patient VI-OS at 6 months of age were only specific for the
patient's autologous env from his 20 day isolate. Yet , at 19 months, the per measured
against this same env were derived from thee pools of cross-reactive pCT and therefore
were probably not from this previous pool. pCTL cross-reactive with al thee env
(autologous from 20 day and 6 month isolates and III) were the most highly represented
withn the total per reactive to the 20 day autologous env (47% of al per against env
measured) (figure 13). Although there were no detectable per against autologous env
from the sixth month isolate at 6 months of age, by 19 months per reactive to this env
could be measured and these were also derived from cross-reactive pools of per only.
The same was tre of per responsive to II env at ths time point.
At 3 months of age, the pCT recognizing both autologous env s from the 1 month
and 3 month isolates were primarly cross-reactive (62%) with a small percentage being
specific only for env from the 1 month isolate (19%) or the 3 month isolate (19%) (figure
14). However, at 7 months of age, although the percentage of 1 month-env specific per
remained the same (16%), the cross-reactive pool decreased by nearly half (35%) and the 3
month-env specific pCTL percentage increased to more than double (48%). Curiously, at 
year of age, when the patient recognized heterologous env, the majority of the per were
cross-reactive either to al thee env s (19%) or to combinations of two. However, the
percentage of per specific only for the 1 month env remained the same thoughout
;S'
(17% ).
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Figure 1 L Percent autologous env-specific, nm env-specific and cross-reactive per 
cord blood (A) and at 6 months (B) of patient VI-06.
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Figure 11. Percent autologous env-specific, nrn env-specific and cross-reactive per 
cord blood (A) and at 6 months (B) of patient VI-06.
Individual wells set up in limiting dilution from PBMC from patient VI-06 from cord blood
and 6 months of age were analyzed separately for cross-reactivity to both env-expressing
targets used in the assay. Precursor frequencies of cross-reactive CI were obtained as
described in the Materials and Methods section and the percentages of cross-reactive and
singly-reactive per were calculated based upon these frequencies.
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Figure 12. Percent autologous env-specific, UIB en v-specific and cross-reactive pCT 
12 months of patient VI-05.
Individual wells set up in limiting dilution from PBMC from patient VI 05 from 12 months
of age were analyzed separately for cross-reactivity to env-expressing targets used in the
assay. Precursor frequencies of cross-reactive er were obtained as described in the
Materials and Methods section and the percentages of cross-reactive and singly-reactive
pCTL were calculated based upon these frequencies.
Figure 13. Percent autologous env-specific, II env-specific and cross-reactive per at 6
months (A) and 19 months (B) of age of patient VI-08.
Figure 13. Percent autologous env-specific, II env-specific and cross-reactive pCTL at 6
months (A) and 19 months (B) of age of patient VI-OS.
Individual wells set up in limtig dilution from PBMC from patient VI-08 from 6 and 12
months of age were analyzed separately for cross-reactivity to env-expressing targets used
in the assay. Precursor frequencies of cross-reactive er were obtained as described in
the Materials and Methods section and the percentages of cross-reactive and singly-reactive
pCTL were calculated based upon these frequencies.
Figure 14, Percent autologous env-specific, II env-specific and cross-reactive pCTL at 3
months (A), 7 months (B) and 12 months (C) of age from patient VI- II.
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Figure 14. Percent autologous env-specific, II env-specific and cross-reactive pCT at 
months (A), 7 months (B) and 12 months (C) of age from patient VI- II.
Individual wells set up in litig dilution from PBMC from patient VI- II from 3, 7 and
12 months of age were analyzed separately for cross-reactivity to en v-expressing targets
used in the assay. Precursor frequencies of cross-reactive er were obtaned as described
in the Materials and Methods section and the percentages of cross-reactive and singly-
reactive per were calculated based upon these frequencies.
',;\
E. Precursor Frequency Analysis of CTL and against HLA-A2 restrcted epitopes within
PBMC of patients VI-06 and VI-08.
Patients VI-06 and VI-08 both possess the HLA-A2 haplotype to which several env
CI epitopes have been reported to be restrcted (8, 87). These epitopes were primary
based upon IIB env sequences. Takng advantage of this, the abilty of patient VI-
who had a very early group-specific CT response, to recognize thee of these published
epitopes was examned. Sequence analysis of ths patient's env clones in regions
containing these epitopes was also performed. The same was done for patient VI-08.
Pep tides containing these epitopes were used to pulse targets, and pCT were measured by
LDA. Table 11 shows the sequences and locations of the epitopes and the peptides used to
measure pCI in this assay. PBMC were examned for pCT from patient VI-06 at 3
months of age against these the peptides. Two of the peptides, 1923 and V3- , were
recognized at a range of 91-357 pCTU10 PBMC (figure 15 and table 12). The 
precursor frequency against peptide 1930 was not significantly higher than background.
Sequence analysis of these epitopes within env clones derived from this patient at 1 day of
age reveals complete conservation of sequence with the published epitopes within epitopes
1923 and 1930 (figure 16) and a relatively high degree of conservation within that of V3-
However, sequence analysis of env clones generated from ths patient at 6 months of age
show a greater amount of divergence from the 1 day clones within the epitope V3- 1 (figure
17). In contrast, these clones show very litte divergence within epitopes 1923 and 1930
from the 1 day clones. Although patient VI-08 displayed II responsiveness by at least 19
months of age , PBMC taken from this patient at 15 months of age did not demonstrate any
measurable per to any of these A2-restrcted epitopes, even though there was almost
complete conservation between the epitope sequences published and that of the patient'
env clones derived from 20 days (figure 18) and 6 months of age (figure 19). Sequence
j u varation was only observed within the V3- 1 epitope withn some of the 6 month env
clones to a very minor extent.
Table 11. A-2 restrcted epitopes
Epitope Amino Peptide Epitope
Acids:t Name
WVYYGVPVW TICA 34- VPVWTICASDAKA Y (1923)
WDQSLKPCVKL TP 112- 124 WDQSLKPCVKL TPLCVTNC (1930)
SVEINCTRNNKSI 291-307 SVEINCTRNNKSI (V3- 1 )
Epitopes 1923 , 1930 and V3- 1 are known Cf epitopes.
* The amno acid sequences of the epitopes reported by Clerici et al (87) and Dadaglio et 
(8).
:j Amno acid location of the epitope based upon the UIB strain of HIV-
Amo acid sequences of the peptides used in our study to measure pCI frequencies
directed at these epitopes
'e..
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Table 12. Precursor frequency of CTL recognizing A2-restrcted peptides of patient VI-
at three months of age.
Peptide pCTUl PBMC
LCL* 98 (75- 129)
189 (146-244)1923
1930 128 (98- 167)
26 (17-40)LCL*
V3- 383 (290-505)
Precursor frequencies of er were measured by LDA in PBMC of patient VI-06 at 3
months of age agaist the peptides described in table 13. Target cells were pulsed with
peptides as described in the Materials and Methods section. separate assay was
performed to detennne the precursor frequency of CTL recognizing the V3- 1 epitope. The
frequencies of per recognizing autologous B-LCL in the absence of peptide were
quantitated to detennne background pCTL frequencies.
* B-LCL values are from two separate assays
Figure 15. Precursor frequency analysis agaist 1923 and 1930 (A) and V3-1 (B) of
patient VI-06 at 6 months of age
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Figure 15. Precursor frequency analysis agaist 1923 and 1930 (A) and V3- 1 (B) of
patient VI-06 at 6 months of age
CI precursors were quantitated using limitig dilution assays followed by in vitro
stimulation of PBMC from 3 months of age. HIV - 1 specific frequencies were calculated as
described in the Materials and Methods section. er precursor frequencies were measured
against autologous B-LCL in the absence of peptide and B-LCL pulsed with peptides
corresponding to epitopes 1923, 1930 and V3- 1. Numbers in parantheses are pCTL values
with background subtracted. Spontaneous release was c: 30% for al tagets shown. The
cut-off for a positive response was 10% for the two assays.
Figure 16. Sequence analysis of A2-restrcted en epitopes withn env clones derived
from patient VI-06 at 1 day of age.
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Nucleotide sequences were obtained from env genes ligated into the pCR3 (In Vitrogen)
backbone. Plasmid DNA was extracted from transformed bacteria and purified using acid-
phenol as described in the Materials and Methods section. Double-stranded DNA
sequencing was performed using a modification of the Sequenase Version 2.0 (United
States Biochemical) protocol described in the Materials and Methods section. Both strands
were read by hand.
of DNA were sequenced using upstream and downstream primers and DNA sequences
. -
Figure 17. Sequence analysis of A2-restrcted CI epitopes within env derived from
patient VI-06 at 6 months of age.
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Figure 18. Sequence analysis of A2-restrcted er epitopes within env derived from
patient VI-08 at 20 days of age.
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Figure 19. Sequence analysis of A-2 restrcted CI epitopes withn env derived from
patient VI-08 at 6 months of age.
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F. ADCC antibody titers against autologous and heterologous env proteins within patient
plasma.
Previous work in our laboratory has demonstrated the lack of measurable titers of
ADCC antibodies withn the first year of life in the majority of vertcally infected infants.
Again, the env gene used for these studies was UIB. Therefore, the env recombinant
vaccinia vectors derived from clical isolates were used to determe whether there were
measurable titers present to autologous env sequences during early infancy. Plasma from
patients VI-06, VI-05 , VI-08 and VI-ll was titrted against UIB and autologous env at
four different tie points, which ranged over the ages of 2 months to 24 months. The
antibody titers present from 2 months to approximately 6 months of age were
indistinguishable from maternal antibody. Therefore, antibody measured subsequent to 6
months was considered to be infant-derived.
Not surprisingly, plasma from patient VI-06 was strongly group-specific,
demonstrating high titers to both autologous env and nIB (figure 20). Titers rose
approximately l00-fo1d from 2 months of age to 6 months of age, against autologous and
heterologous env, indicating vigorous antibody production during these early months by
the patient. These high titers were maintained through at least 25 months of age.
AJCC antibody titers of patient VI-05 were type-specific from 6 to 20 months 
age, with responses only to autologous env derived from 2 months of age (figure 21).
Maternal ADCC antibody titers were measured against both nIB and the patient' s 2 month
autologous isolate at 2 months of age at equivalent titers. Interestingly, the autologous env
derived from virus present at 6 months of age was not recognized by ADCC mediatig
antibodies (nor was it recognized by matemal antibody). ADCC antibodies from 2 to 
months of age were maintaned at low titers but then dropped lO-fold lower between 6
.I.
months and 12 months and then were maintaed just above the level of detection for the
assay from 12 to 20 months.
High ADCC titers could be measured in the plasma of patient VI-08 prior to 6
months of age against both UIB env and, curiously, VI-08' s autologous 6 month env but
not the 20 day env (figure 22). Titers to II were 10- fold lower than that agaist
autologous env. These titers dropped precipitously by 6 months, at which tie point only
very low 20 day autologous env titers could be detected. From 6 months to 24 months of
age , ADCC titers continued to rise , again , only against the 20 day autologous env.
Detectable ADCC titers were completely lacking in the plasma of patient VI- II from
2 to 6 months of age (figure 23). However, between 6 and 12 months of age, ADC titers
to all three env s (autologous 1 month, 3 month and II) could be measured. Titers were
at least lOG-fold grater to autologous env derived from 3 months of age at the 24 month
time point.
Lack of ADCC titers against the recombinant env-expressing vectors could be
explained by either an overall inability of a certn env to be a taget for ADC or by an
intrnsic inability of the patient to generate ADCC antibody to that parcular env. To test
for the former, titers of ADCC antibody were measured in plasma that had been pooled
from HIV- l infected individuals with hemophilia against al of these patient-derived env
High titers were detected in this pooled plasma agaist all of the clinically-derived env
(figure '24).
Figure 20. ADCC titers of patient VI-06 over time against autologous and II env.
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ADCC antibody titers were measured in plasma of patient VI-06 at 2, 6, 12 and 24 months
of age as described in the Materials and Methods section. The lit of detection of the
assay is a titer of 10- , therefore, any data point below 3 on the Y-axis is interpreted as lack
of ADCC antibody titer. The env-expressing targets ar autologous B-LCL infected with
env-recombinant vaccinia viruses expressing II env (II) and env derived from an ID-
;f: 1 isolate of patient VI -06 at 1 day of age (vv AR - D).
Titers below 3 represent values below detection of the assay.
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Figure 21. ADCC titers of patient VI -05 over time against autologous and Il env.
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ADc=C antibody titers were measured in plasma of patient VI-05 at 2, 6, 12 and 20 months
of age as described in the Materials and Methods section. The lit of detection of the
assay is a titer of 10 , therefore, any data point below 3 on the Y-axis is interprcted as lack
of ADCC antibody titer. The env-expressing targets are autologous B-LCL infected with
env-recombinant vaccinia viruses expressing nm env (TIm) and envs derived from au
HIV- l isolate of patient VI-05 at 2 months (vvHE-2M) and 6 months (vvHE-6M) of age.
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Figure 22. ADCC titers ofpaitent VI-08 over tie against autologous and II env.
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ADCC antibody titers were measured in plasma of patient VI-08 at 2, 6, 12 and 24 months
of age as described in the Materials and Methods section. The lit of detection of the
assay is a titer of 10- , therefore, any data point below 3 on the Y-axis is interpreted as lack
of ADCC antibody titer. The env-expressing targets are autologous B-LCL infected with
env-recombinai1t vaccinia viruses expressing UIB env (UIB) and envs derived from an
HIV- l isolate of patient VI-08 at 20 days (vvJA-20D) and 6 months (vvJA-6M) of age.
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Figure 23. ADCC titers of patient VI- II over time against autologous and II env.
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ADCC antibody titers were measured in plasma of patient VI- II at 2, 6, 12 and 24 months
of age as described in the Materials and Methods section. The lit of detection of the
assay is a titerof 10- , therefore , any data point below 3 on the Y-axs is interpreted as lack
of ADC antibody titer. The env-expressing targets are autologous B-LCL infected with
env.;recombinant vaccinia viruses expressing nIB env (HIB) and envs derived from an
HIV- l isolate of patient VI- II at 1 month (vvRO- IM) and 3 months (vvRO-3M) of age.
Figure 24. ADCC titers of pooled positive plasma against patient-derived env s and 
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ADCC antibody titers were measured in plasma which was pooled from HIV - 1 infected
individuals with hemophia and was previously demonstrated in our laboratory to have
broad recognition of HIV - 1 envs of different strains. Targets were B-LCL infected with
III-env-expressing vaccinia virus and B-LCL infected with recombinant vaccina virses
expressing each of the env genes derived from the HIV- l isolates of patients VI-06, VI-05,
VI-08 and VI- II.
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CHAPTR IV: DISCUSSION
A. Env clones derived from low passage virs co-culture are relevant to the immune
response.
In order to rnmi the chance of amplifying defective fI -1 env sequences, we
chose to constrct the env-expressing recombinant vaccinia vectors with env genes
amplified from cultured virus. Many studies have demonstrated the outgrowth of
predominant varants of limited diversity in viral co-culture which were not predominant in
vivo at the tie point at which the culture was established (17, 89-91). These varants
selected for in culture may be minor varants in vivo for a number of reasons: they may be
suppressed by an active immune system, anti-retroviral therapy or they are a newly evo1veci
quasispecies which wil emerge as a predominant varant at a later tie point. Evidence by
Ddwar et al (17) has demonstrated the latter possibility in heterodup1ex tracking analyses
in which cultured virs was observed to be a minor varant in vivo at the time of culture but
at a later time point was present in abundance. Delwar s study suggests that viral varants
derived from culture are also present in vivo at levels necessar to stimulate inununity. The
absence of anti-retroviral therapy in these patients at each of the time points from which the
env vaccinia recombinants were generated supports the notion that these varants were not
suppressed in vivo and expanded in vitro due to absence of the drg. Finally, the abilty of
CT precursors from these patients to recognize env protein products from the env
sequences derived from cultured virus suggests that these sequences were present in vivo.
Additionally, studies which have compared the selection of varants in culture of lited
diversity to that present in vivo have maintained these viral cultures out to at least 28 days
(90). The en v genes used to generated recombinant vv in our studies were amplified from
virus which had been cultured for less than a week and passaged either once or twice which
may have minimized the in vitro selection of varants.
Alternate sources of template for amplification of viral env sequences include
proviral DNA present in uncultured PBMC or viral RNA present in plasma virions.
Varants present withn uncultured PBMC ar considered to be a collection of both
replicating virus and "graveyard" sequences of defective viruses. Thus, generatig env
clones from circulating, unculturedPBMC was less desirable due to the risk or clonig
these defective sequences. The use of viral RNA as template was also less desirable but
from the standpoint of practicality. Amplification of the enti env gene would have had 
include a reverse transcription step followed by DNA PCR. Generating a PCR product
from reverse transcription of a template of ths size in sufficient quantities to clone would
have been technically infeasible. Therefore, in the interest of obtaing biologically relevant
env clones which would be used to gauge immunity in patients VI-06, -05, -08 and - 11,
we chose viral co-culture as a source of these clones. Furtermore, studies by Wolinsky et
. . -
al support the notion that concern over varant selection of early infant viral isolates in
culture may be unwaranted. Sequence comparson of the V3 and V4-V5 regions of env
within 2 to 4 month old infants by ths group revealed litte diversity of viral varants
derived from PBMC (18). Given ths level of homogeneity in PBMC-derived virus at
these early tie points, it is reasonable to assume that cultured varants from these same
time points would be representative of the in vivo varant population.
B. Diversity of patient proviral DNA sequences from HIV - 1 nm.
Group-specific er responses can be detected as early as pre-seroconversion 
adults using heterologous viral gene products (29, 36, 92) as targets. Yet we detect only
type-specific CTL responses in infants during the first year of life. With the multitude of
HIV - Cf epitopes that have been mapped to env (93-95) it is diffcult to imagine that
enough overa heterogeneity exists between heterologous and autologous env gene
products withn ths infant population to abrogate recognition of al of these regions.
Indeed , the degree of diveristy between the infant-derived env sequences and HIB (BHlO),
as determned by heteroduplex analysis, was minor (in the rage of 4-5%). Nor could a
shift in the env population toward greater homology with ll over time be an explanation
for the appearance of ll-specific CT by 1 year of age in these patients.. For that matter
patients VI-08 and VI- II demonstrated mior heterodup1ex mobility changes within their
later isolates that would suggest furter divergence from ll.
Although many CI epitopes have been described within env, their relevance to
CTL recognition in vivo is questionable. Many of these epitopes ar detected in assays in
which microgram amounts of peptide are used in the peptide-pulsing of targets (8, 10, 87).
High densities of these peptides on the target cells may result in taget cell lysis by low
affinity/specificity CI which may not interact with in vivo targets strongly enough to
effectively contrbute to the Cf response. er clones obtained by limtig dilution have
also been used extensively to map HIV - 1 epitopes (33, 96-98). Although these studies
provide information concerning class I binding motifs withn HIV - 1 proteins, the actual
representation of these CI clones in vivo remains unclear. Therefore, in spite of the
presence of many potential CI epitopes , a smal number of er epitopes may domiate
the immune response at a given point of infection. If this were tre, the overall sequence
diversity between two env genes as examned by heteroduplex formation analysis may be
relatively uninformative in predicting whether the er response to their gene products
would be group or type-specific. Detecting differences within known HLA-restrcted 
epitopes by DNA sequence analysis would better indicate the broadness of the immune
response. However, if immunologically dominant regions ar present, ths would need to
be done in retrospect afer mapping the dominant epitope.
C. fI specific pCTL were detected in 3 of 4 infants in early infancy
Luzuraga et al (64, 68, 99), using Il-based gene products as targets, have
reported the lack of cirulatig HIV - 1 specific Cf from unstimu1ated PBMC and lack 
detectable er precursors from nonantigen specific stiulation of PBMC within the fIrst
year of life in vertcally inected infants. These CI responses subsequently appear
following approximately one year of age. The presence of HIV - specific er 
vertcally-infected patients older than 12 months has been well-documented by several
investigators (65-67). Each of these studies used laboratory-based viral gene products to
measure er responses. The lack of ID- env-specific Cf precursors within the
PBMC of patients VI-05, VI-08 and VI- II prior to 12 months of age is in agreement with
these results. In contrast, a study done by Cheynier, et al (100) detected ID- II specific
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CTL in three out of six infants less than 12 months of age within circulating, unstimu1ated
PBMC. However, the taget cells used in these assays were P815 cells co-transfected with
HLA-A2 and either HIV- l env, gag or nef. High expression of these transfected genes in
addition to a lengthy incubation tie of effectors and targets (18 hours) could allow for a
less specifIc assay in which an "antigen-loaded" target could be lysed by CTL of weak
affnity. Thus, the results obtained in this study should be interpreted with caution as they
may overestimate the lytic potential of these CfL in vivo.
The results of this study demonstrate the necessity of using autologous virus for the
detection of ID - I-specific CT responses in early infancy in infants infected with HIV -
Prior lack of detection of III-env-specific pCT in these infants was misleading in
suggesting an inability of young infants to mount HIV - I-specific cellular immune
responses. It is now evident that in the absence of detectale er responses to laboratory
HI - 1 strains, young infants possess CI which can recognize autologous viral gene
products and are present at frequencies at which laboratory-strn specific er have ben
measured in older vertcaly infected children (67). In 3 infants, the detection of per
recogniing target cells expressing early isolate env preceded the detection of per
recognizing taget cells expressing IIT env. These type-speific per detected in early
infancy were replaced by cross-reactive, group-specific er by 6 to 12 months of age. 
a fourt infant, per recognizing taget cells inected with HN- II env and early
isolate env were simultaneously detected at 12 months of age.
It is important to note that many techncal problems ar inherent in the constrction
of the assays employed for per quantitation. These techncal diffculties must be kept in
mind in the careful interpretation of the results. For example, only a lited quantity of
PBMC can be obtaied from a young infant. These PBMC, following cryopreservation
are also faily fragile which furter lowers the yield of PBMC afer thawing. Although
there were suffcient numbers of PBMC to perform the assays described above , we could
not deplete for NK cells. As a result, background lysis (although corrected for in the
mathematical analysis) was varably high between time points taen from the same patient.
To control for this varabilty, the same donor was used as a source of feeder ceHs at each
time point and the pCT from each time point was measured on the same day with the same
target B-LCL. Despite these precautions , increased background lysis could still be detected
in PBMC from paricular tie points. This could be due to the original composition of
cells of lytic potential within the starng PBMC population. Although using the same batch
of B- LCL targets for each time point decreased the varabilty of susceptibilty of target cells
to lysis, it was techncally difficult to mi target and effector cells from each tie point at
the same time. Therefore , there was a tie differential between the application of target
cells to effectors from one time point in relation to the other. The tie lag between the two
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applications could also contrbute to higher background lysis due to increased taget
fragility over time. The results of ths study ar therefore useful in determg whether a
CI response is present withn PBMC from a parcular tie point if pCT quantities
exceed background. However, we ar lited in the comparson of absolute quantities of
pCT able to recognize a specific env gene product from two different tie points due to
the background lysis varabilty between these tie points.
PBMC of patient VI-06 taken from cord blood appeared to have some reactivity to
autologous env taken from a 1 day isolate. Whle ths patient was also shown in a previous
study to demonstrate measurable per withn PBMC of cord blood against ID - gag
gene products (68), the autologous env pCT frequency was not significantly higher than
background lysis due to slightly overlapping 95% confidence intervals" However, we
believe the increased pCTL values obtained against 1 day autologous env are real. Matemal
lymphocytes within cord blood could mediate cytolysis, however HLA typing
demonstrated only fetal lymphocytes within the cord blood. Even more surprising was the
demonstration of a group-specific er response withn the PBMC of ths patient as early
a..'- 6 months of age. Vigorous cr activity to both ID- II env and gag gene products
within PBMC measured directly in bulk without prior in vitro stimulation was seen during
early infancy (68). Positive cord blood viral cultures and DNA PCR from this individual
supports the diagnosis of in utero infection. If viral heterogeneity is considered to
contrbute to a broader, more-group specific er response, than one could theorie that
this parcular patient s immune system, by 6 months of age, had encountered an aray 
variants. In support of this, HIV- l RNA copy number had risen from 49,000 copies/ml at
birth to 1 300,000 copies/ml by 4 months of age. Even clones that were derived from this
patient cultured virus from at 1 day of age demonstrated a greater heterogeneity than that
seen in clones from this patient s virus isolate at 6 months of age or in clones of viruses
from the other thee patients at any of the tie points studied. At 1 month of age, the
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patient received anti-retroviral mono therapy and by 5 months of age was being trted with
two anti-retrovirals concorntatly perhaps accounting for the decrease in vir
heterogeneity seen in the 6 month clones. One possible explanaton for the degree of
heterogeneity seen so early in infancy could be infection which occurd early enough in
utero to allow for the generation of many variants. In the majority of cases, prima
infection involves the successful outgrowth of perhaps one to only a few viral varants (16-
, 101) due to the transmission of a single or a few viral varants. If the varants withn
VI-06 were derived from a single progenitor and beame heterogeneous durng gestation it
would seem that selective pressure was applied during ths tie to the virus to diversify.
Possible contrbutors to selection would be maternal antibody which can traverse the
placental barer or feta imune responses. On the other hand, it is possible that in the
case of this infant, early in utero infection was not so much a factor as, perhaps, an
unusually large vir inoculum. In ths case, one might speculate, that several varants
might have the abilty to be successfully transmitted. In fact, co-infection by more than one
varant within acute adult seroconverters has been documented through heterodup1ex
mobility and DNA sequencing analysis (17 , 102) Alternatively, the class I alleles of ths
patient in combination with the TCR repertoire may allow for presentation and recognition
of a wider assortment of CTL epitopes than what is seen with most patients. Whatever the
case may be, this infant who was capable of early group-specific imune responses also
possessed an unusually high early viral burden. Although ths patient's imune responses
were vigorous, it suggests that viral replication outstrpped the immune response very early
on.
PatientVI-05 had measurable CT responses directly from PBMC against HIV-
en v by months of age as determned previously in our laboratory. In contrast with
patient VI- , this patient did not demonstrate per withn cord blood to any of the envs
tested. Although both patients were infected in utero, the differences in er responses
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could relate to the factors described for patient VI- , namely timig of infection or vir
dose at transmission. Interestingly pCTL diected against ths patient' s 6 month env could
not be detected at 12 months of age although there were significant frequencies of 
against autologous 2 month and Il envs. Lack of er recognition could be due to vir
escape from CI recognition of the enti env gene. Alternatively, divergence of ths
patient's vir isolates by 12 months of age could have resulted in a CI epitope
sequence(s) which was less simiar to that present at 6 months and more lie Il. The
CTL stimulated in response to the virus present at 12 months may not have specificity for
ths earlier env.
As with patient VI- , PBMC of patient VI-08 had previously been examned for
diectly measurable CI activity against ID- II env and gag gene products in bulk
assays and in LDA assays following nonspecific in vitro stimulation. Env and gag-specific
CTL were not detected by either method unti 11 months of age at which time very low env
lysis could be measured directly. Detetion of per at 6 months of age against VI-
autologous env taken from the 20 day isolate demonstrated the abilty of this patient to
mount a cellular HIV- l specific imune response in early infancy. Additionally, it was
observed that at 6 months of age, although this patient was able to recognize env from a 20
day viral isolate, pCI to the env of the 6 month virus were undetected. A possible
explanation for ths result that at the tie of sampling, the varant was not predominant in
vivo but beame so during the culturing process. Therefore, the amount of antigenic
stimulation needed in vivo for er proliferation may not have reached threshold unti 
time point beyond 6 months. This idea is furter supported by the fact that by 19 months,
pCI recognizing the 6 month env are readily detectable. Alternatively, the CI epitope(s)
within this env may represent escape mutants to which the per at 6 months of age were
unable to respond. By 19 months of age , a new env epitope may have become dominant
which was present in all three envs.
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In previous studies , patient VI- II did not have diectly measurable er responses
in bulk within PBMC against II env or gag gene products prior to the first year of life.
Unlike patients VI-05 and VI-08 however, pCTL were detected by 3 months of age against
II gag by nonspecific in vitr stimulation in LDA but not against Il env. Recognition
of both autologous env s derived from viral isolates at 1 month and 3 months of age by
patient VI- II at al th tie points examed is not surprising when one considers how
similar the two env genes appear by heterodup1ex analysis. Heterodup1exes fonned
between pNL-3 and these two env clones migrated at approximately the same speed
although the lower band of the heterodup1ex doublet fonned between pRO-3M and pNU-
was slightly higher than the same band in the heterodup1ex fonned between pRO-1M and
pNL-3. This suggests a small degree of sequence heterogeneity between the two.
D. Role ofCT in primar infection
Although HIV - I-specific pCI are present during early infancy in vertcaly
infected infants, their anti-viral role is unclear. Patient VI-06 demonstrated per specific
for both gag and possibly autologous env in PBMC of cord blood as well as IIIB env
pCTL present withn 3 weeks of life (68). CTL precursor frequencies against II gag and
env gene products were detected consistently over a period from birh to 16 months of age
(68). Recent studies (29, 36) have correlated the presence of HIV- l-specific pCTL in
adults during seroconversion with control of acute viremia. Yet
, this patient s viral load
was high at birt and continued to climb over the patient' s first 4 months of age where it
peaked at 1 300 000 RNA copies/rn of plasma. The abilty to measure ID- l-specific
CI responses in the PBMC of inected adults without prior in vitro stimulation is a
hallmark of HIV - 1 infection in this population. Although CT precursors were readily
detected in this patient during the first few months of age, er responses withn
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unstimulated PBMC were not examned until 4 months of age. By 4.5 months of age, ths
patient demonstrated measurable er responses against both env and gag gene products 
PBMC which were not stimulated in vitro (68). Although the bulk er responses withn
this patient prior to 4 months of age is unkown, it is possible that the ID - I-specific 
which we have detected following in vitro stimulation may not be expanded to a sufficient
extent in vivo for their diect detection. In fact, in vitro stiulation has been demonstrated
to be necessar in order to detect ID - I-specific er in vertcaly infected chidren older
than 12 months of age (67). Limted expansion of ID- l-specific en may relate to the
naive state of the imune system in infants and may be prove less effective in controllig
early viremia. Type-specific CT responses could not be measured diectly from
unstimu1ated PBMC in these patients due to the limited number of cryopreserved cells
available for study but would have been infonnative as to the possible role of er in ID..
1 infection of infants.
E. Phenotype of effectors mediating target cell lysis in PF A
The phenotype of the effector cells in adults and children mediatig cytolysis
against env-expressing target cells in CTL assays has been reported to be a combination 
CD8 , T lymphocytes and CD 16 (NK) lymphocytes which ar presumably aned with
ADCC mediating antibody via their Fc receptors (64, 67, 100, 103, 104). Detennnation
of effector cell phenotype was accomplished primarly though depletion of cell populations
using specific antibody and complement. However, ths method can result in overal cell
loss in addition to depletion of a paricular cell phenotype. Therefore, due to the lited
number of cells avaiable for this study, NK cell depletion of patient PBMC prior to
analysis was impractical. However, NK mediated cytolysis of env-expressing targets by
ADCC can be ruled out with a great degree of certainty based upon ADC antibody titers
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specific for these same env targets at these same tie points. For example, PBMC of
patient VI-05 at 12 months of age had detetable pCT to HIB env in the absence of
measurable ADC antibody to ths same env at ths same tie point. Ths lysis seen
against II env, therefore , most likely cannot be attrbuted to ADCC. The same is tre for
recognition of patient VI-08' per ofII env and autologous 6 month env at 19 months
of age and patient VI- ll ' per recognition of 1 and 3 month autologous envs at 3 and 7
months of age. ADCC antibody titer was not detected against IIIB or autologous 6 month
envs in patient VI-08' s plasma at 19 months of age or autologous 1 and 3 month envs at3
and 7 months of age in patient VI- II' s plasma. In furter support of the notion that NK
lysis did not playa major role in cytolysis of targets in these assays, Buseyne et 
demonstrated that cytolysis mediated by a PBMC effector population stiulated in vitro by
similar means was uneffected by CD16 depletion (65). It is possible that there are NK cells
aned with AOC mediating antibody within these patient PBMC even though this
antibody cannot be detected in plasma. However, considering that these titers are below
detection, these would be expected to contrbute to cytolysis to a rather minor degree. It is
also possible thaf cytolysis could be due to diect NK cell lysis of env-expressing targets
however, it is unlikely that different envs would be differentially recognized by these cells.
In addition, it is notable that env cytolysis did not occur in unstimu1ated bulk assays
performed previously in our laboratory on these patients, suggesting that NK effector
paricipation was minimal.
F. Fluctuating patterns of recognition of autologous env sequences
The term "irnunodominance" in the CTL response against ID - 1 has been used to
describe two different situations: in one , the term applies to an antigenic property of the
virus alone, in the other it applies to the interactive dynamcs of the imune response with
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viral replication. In the first, a region can be considered irunodominant within a vir
protein if several CI epitopes are present withn it which ar restrcted by a varety of
HLA class I hap10types. CTL from most individuals with varing HLA class I aleles can
recognie peptides from ths immunodomiant region. However studies mapping
immunodomiant regions do not address whether the CI response against this region
represents a dominant response within a paricular individual. Again
, as described above
low affinity er could possibly contrbute to ths en response measured in vitro. 
example of an immunodominant region withn nef was described by Couilin et al (amo
acids 73 144) which was recognized by er of most seropositive adults tested (10).
However, they observed a population of patients whose CI recognition of nef did not
map to this region although they possessed the appropriate class I alleles for restrction.
Sequence analysis of isolates from these patients revealed mutations within ths region
which reduced or elimiated CI responsiveness. From this, one could speculate that
CT directed to peptides from ths region may have comprised the dominant imune
response to nef at one time and that immune pressure resulted in the mutations allowing for
. CT escape. However, without a sequential study over tie of er recognition of ths
peptide coupled with epitope sequencing of isolates, it is diffcult to interpret this data with
regard to a dominant immune response.
The second situation to which the tenn immunodominance is applied is that in
which one CTL epitope within a viral gene product dominates the immune response to that
viral protein (even in the presence of several potential CI epitopes within the viral
protein). Immunodominant peptides within viral gene products from varous viruses have
been described extensively in the murine system (l05- 109). Although demonstration of
immunodominance within this model is facilitated by the inbred backgrounds of these
anmals coupled with a less diverse HLA class I repertoire than that seen in humans
infonnation derived from murine models can be used to furter our understanding of
1'1'
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human immunity. HIV - 1 specific CI responses diected against reverse transcriptase
(110) and en v (111- 113) in mice have also been mapped to immunodominant epitopes. For
example, Takahashi et al described an immunodomiant epitope withn the V3 loop of
gp160 recognized by H- mice imunid by a recombinant vaccinia vector expressing
the env gene of HI - Il (111). H- mice similarly immunized were completely lacking
in gp160 er responsiveness. The abilty of the H- mice to mae class IT helper
responses to gp160 (114) as well as vaccina suggested that er unresponsiveness in ths
strain of mice was associated with a lack of env specific class I MHC molecule-restricted T-
cell responses. CT responsiveness in mice of a paricular class I haplotype toward one
predominant epitope could be miored in the human ID - 1 cellular immune response. For
instance, Lieberman et al, using nonspecific aly stiulated T cell lines from ID positive
individuals, mapped the CT response against env and reverse transcriptase to one or two
isolate-invarant epitopes (34).
Of course, with increasing varant complexity in HI - 1 infection, increasing
numbers of er epitopes would probably be recognized with a dependence upon
fluctuations in the varant population. Nowak et al has proposed a matematical model
which attepts to reflect the dynamcs of CI activity in response to these fluctuations in
HIV- l quasispecies (115). His modeling is based upon observations of mv - 1 gag-
specific CT activity followed for 55 months within two HIV - 1 infected individuals with
hemophilia. The peptide-specificity of the gag er response within one patient did not
change over the course of the study. Additionally, almost al the viral varants of this
patient sequenced over the course of this study retaned this index sequence. In contrast
the second patient' s gag-specific CTL response alternated at parcular tie points over the
course of the study among three gag epitopes. Sequence analysis of this patient's varants
over tie within these thee epitopes revealed one amno acid substitution within each.
Gag specific er of this patient could also respond to these mutant epitopes.
-- -
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oscilation of the viral varants present over time was observed in this patient which seemed
to corrlaie with a fluctuation of er responses against either wild type or mutant peptide
specificities. At certn tie points, only wild type or mutat peptide were recognied
exclusively even though the varant caring that sequence was present. Interestingly, the
fIrst patient remained well, whereas the second progressed to AIS within 8 years. The
model proposed by ths study attempts to describe these oscilations withn er responses
and varant epitope sequences in mathemacal term. With this model there is a
prediction of competition between different epitopes which can result in irunodominance
of one despite the presence of the other. Ths could happen in a situation in which there is
a stronger er response to the first epitope compared to the second. Therefore, the
stronger response requires a lower theshold of antigenic stimulation and replication of
varants to which ths response is diected is controlled by these er at a level below that
needed to stimulate the weaker response. However, once viral heterogeneity occurs, the
situation becomes much more complex and the pattern of er responses may become
dependent upon fluctuations in varant sequences.
Two env-expressing recombinant vaccinia vectors were derived from patients VI-
and VI- II from early tie points of infection and used as targets to evaluate early 
responsI veness. Selective recognition of only one autologous env gene product was
. observed with pCT quantitation of patient VI-08. Ths varabilty in CI responsiveness
to autologous and UIB envs in er precursors quantitated in patient VI-08 over tie may
be representative of the dynamcs of cellular immunity in the face of viral diversity. For
example, at 6 months of age CTL precursors only recognized the env gene product derived
at 20 days of age. Although there is a strong likelihood that sequences containing 
epitopeswere shared between the patient' s autologous envs and UIB , neither the 6 month
autologous env nor HIB env were recognized by pCTL from this time point. This strongly
points to an immune response within patient VI-08 at 6 months of age which was
-J-
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dominated by er specific for possibly one epitope. Lak of detection of per agaist
the autologous 6 month env at 6 months of age may have been due to an amno acid
sequence change withn this irunodominant epitope. This amo acid change could
either result in complete loss of recognition of this epitope with a concorntat shift in
peptide irunodominance within the host or the proliferation of a new pool of 
precursors able to recognize this new epitope. If the latter case resulted, a shift in peptide
irunodominance could sti occur due to weaker recognition of ths mutated epitope by
ths new pool ofCTL. A shift in immunodominance to anepitope(s) more commonly
shared between both autologous envs and II could explain the evolution by 19 months of
age of group-specific env CTL responses.
Escape from CTL recognition withn parcular epitopes has been well-documented
within HIV- l infection (10- , 116- 123). However, it is frequently unclear as to whether
loss of recognition of one epitope can result in complete abrogation of the CI response to
the entire gene product from which the epitope derived. The complete lack of recognition
of autologous 6 month env by er in patient VI-08 at 6 months suggests that this can
occur. Epitope mapping and varant sequencing are needed for confirmation , however, ths
situation is highly suggestive of complete escape of env from CT recognition.
Precursor CTL of patient VI- , in contrast, were able to recognize both autologous
, env gene products at thee tie points during the first year of age. Unlike patient VI-
the amplified env genes used to generate the vaccinia recombinants from patient VI-
displayed almost identical migration rates on heterodup1ex mobility analysis (tigure 4).
This suggests that sequences within these two genes are very closely related. This is
perhaps a result of amplifying env sequences from isolates taen at two closely apposed
time intervals (1 month and 3 months of age), a result of selective pressures in viral culture
for that parcular env gene or simply a result of less varant diversity within isolates of
patient VI- II compared with patient VI-08. Recognition of both env gene products by
;" ...
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pCTL of patient VI- II at all tie points examned with the fIrst year of lie was therefore
most likely due to a shared epitope(s).
It is importt to point out that the method of in vitro stiulation used in these
assays does not inerently favor the outgrowth of env Cf of any parcular specificity.
Assuming that al of the activated and memory CI present within the PBMC have equal
proliferative potential in response to nonantigen specific stimulation, the proportion of
per directed agaist each target in the assay should be representative of that proportion in
vivo. In this regard, in vitro stimulation without specific antigen provides a trer estimate
of the dominant CI response at that tie point. Antigen-specific stimulation, however
can be importt in providing appropriate conditions for the development of potent ID-
specifIc Cf lines (124) and detection of Cfs specific for epitopes recognized at low
frequency (125). It is also required in order to demonstrate escape from CI recognition
with the greatest certainty.
G. Lack of cross-reactive pCTL in early infancy: immunologic naivete vs 
parial tolerance.
Although viral varants present soon after transmission appear to be genotypically
. homogeneous within the majority of adults and infants, early group-specific 
responses undetectable in vertcally infected infants are readily detected in adults. These
Cf from adults have not been analyzed on a c1onal1eve1
, therefore it is unclear whether
group-specificity is due to cross-reactive pools of Cf or multiple pools of singly-reactive
CTL, however, it seems logical to assume that cross-reactive Cf are parally responsible
for the group-specific response because of viral homogeneity From split-well analyses of
the pCTL measured against autologous and heterologous viral env products in patients VI-
, VI- , VI-08 and VI- II ,a pattern of CTL responsiveness emerges in which the primar
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type-specific response appears to be mediated wholly by singly-reactive Cf. Patients VI-
06 and VI-08 most clearly show ths: Singly-reactive er precursors of patient VI-06 in
cord blood recognized 1 day autologous env in the absence of recognition of lIIB env and
singly reactive per of patient VI-08 at 6 months recognized autologous 20 day env in the
absence of recognition of autologous 6 month env or lIIB. Although patient VI- II also
had pCTL which only recognized autologous virus unti 12 months of age , many of these
were cross-reactive. Ths was probably due to recognition of conserved
imunodominant epitope withn the 1 month and 3 month env sequences. What is of
greater interest, however, is that as the infant matured, there was a transition in the nature
of the reactivity of the population of per responding to env. er precursors from early
tie points were predomiantly singly-reactive resulting in type-specific CI responses.
Whereas, the majority of group-specific Cf at later time points were cross-reactive.
A parameter unique to early infant immunity which may allow for only sing1y-
reactive , type-specific CTL responses could be the naive state of the infant immune system.
Hypothetically; adults, whose imune systems have been primed by many previous vir
infections, possess memory CTL to these viruses which can expand in response to mV-
infection. The proliferation of non HIV -specific memory CT in response to ID infection
argues for the ability of the TCR on these cells to cross-react with HIV and heterologous
virus. There may be a population of cells within these cross-reactive memory CI which
might also be more likely to elicit a group-specific HIV - 1 response by their cross-reactive
nature and may greatly contrbute to the more vigorous CI response seen in adults.
Further support comes from the fact that the frequency of CI precursors detected withn
early infant PBMC against autologous virs appears to be much lower than that seen in
adults against heterologous virus (27-29, 32 , 126).
Indeed , this phenomenon has been convincingly demonstrated in a murine model.
Selin et al examned the clonal specificities and cross-reactivities of CfL in LCM immune
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mice later challenged with a heterologous viral infection such as Pichinde or vaccina virus
(127). Acute infection with the second virus resulted in expansion of memory CTLs
specific for LCM in which a large portion were cross-reactive with the second virus.
Previous studies by ths same group had also reported the expansion of a population of
allospecific CI during acute LCM infection, many of which were also cross-reactive
with LCMV (128). TCR cross-reactivity has also been demonstrated within the context of
HIV - 1. For example, some studies have demonstrated the abilty of aloactivated 
lines to also recognize regions of env (129, 130). Although C1erici et al (130) interpret
their observation as a mechansm of HIV- l pathogenesis through autoreactivity, it is more
likely a natural phenomenon demonstrable with many different virses. Additonal1y, Shiai
et al (131) demonstrated TCR cross-reactivity to two diferent epitopes withn env in a
murine CT line in which there was preferential Vp usage.
Unlike adults, the immune system of young infants is not composed of memory
pCT poised to expand upon antigenic stimulation. Theoretically, anti-viral responses
must arse primarly frl?m naive CTL p ecursors. This might result in a delayed anti-HIV-
CI response which may be weaker than that seen in adults. Cross-reactive CI may
begin to appear as the infant s imune system accounters a greater complexity of HIV-
viral variants as well as concomrtant heterologous viral infections. Activated ClL
derived from a smaller initial population may make lower overall contrbutions to the HIV-
memory CTL pool due in par to elimination of many of these cells through apoptosis (132-
136). Therefore , especially in the infant, the immune system may be constantly strggling
to keep up with evolving quasispecies. This could be an important factor in rapid disease
progressIOn.
Alternatively, type-specific responses in early infancy in ID- l vertcally infected
infants may be due to paral tolerance. Infants become infected with HIV - 1 at a tie when
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the cellular immune system is being vigorously edited and revised on the basis of its abilty
to discrinate between self and nonself both peripheray and withn the thymic
environment. ID - 1 antigen may be viewed as self-antigen during ths process and ID-
reactive Cf may be deleted or anergized. The abilty of ID -1 to infect and replicate
within professional antigen presenting cells such as macrophages and its presence on
dendrtic cells may allow for activation of a small population of ID -1 reactive er which
have escaped tolerance induction. Ths paral break in tolerance may originaly be dicted
at a limited aray of viral epitopes, resulting in a ty-specific Cf response. Recognition
of these initial epitopes by Cf may lead to an expansion of er responsiveness in which
a progressively greater number of viral epitopes may be recognized. The expansion in
epitope recognition may hypothetically result from a phenomenon observed in models 
autoimunity referred to as epitope spreading (137, 138) in concert with a diversification
of HIV - 1 varants toward viral gene products whose sequences bear less resemblance to the
original to1erizig varants. The group-specific CI responses detected by 12 months of
age may evolve in ths manner.
One might expect HIV- l-specific tolerance to occur in infants who have become
infected in utero. However, infants infected both during the in utero and intraparum
periods display the same pattern of CI responsiveness. Although it is not definitively
. known whether antigen encountered by infants during or shortly after birth is to1eIizing, the
protection of infants from vertcal transmission of Hepatitis B Virs (HBV) by active
vaccination at birth suggests that they are able to recognize an immunogen delivered during
this period as non-self. However, it is also possible that antigen presentation may playa
role in induction of tolerance as the HBV vaccine, being a non-infectious paricle, may be
presented to the immune system differently than HIV -
. (
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H. Precursor Frequency Analysis of CTL against HLA-A2 restrcted epitopes withn
... _
PBMC of patients VI-06 and VI-
The peptides 1923, 1930 and V3- 1 all contain CTL epitope sequences defined in the
literature as being HLA-A2 restrcted (8, 87). All thee of these sequences are based upon
HIV- nm env. Fortuitously, two of the patients, VI-06 and VI-08, possessed the 
haplotype allowing for the possible mapping of the CTL response. PBMC of patient VI-
at three months of age responded to two of these peptides: 1923 and V3- 1. The precursor
Jrequency against V3- 1 was higher than that seen against the enti env at 6 or 12 months
of age suggesting that this epitope was imrunodominant for ths patient. This was further
supported by the degree of sequence change observed withn ths region between env
clones from 1 day of age and those from 6 months of age. Moreover, precursor frequency
measurements from PBMC at 14 months of age against ths peptide from this patient fell
below detection. It is importt to note that ths region is also par of the V3 loop and may
therefore also be under selective pressures related to neutralizing antibody and/or vir
tropism.
On the other hand, pCT from patient VI-08, who also possessed the HLA-
alele and whose env clones from both 20 days and 6 months of age demonstrated high
conservation of these thee peptide sequences did not contain measurable CTL precursors at
6 months of age to IIIB env in which these peptide sequences reside. Furthermore, at 15
months of age , when pCTL to IIIB env were detected, the PBMC from this patient did not
demononstrate pCI to any of these peptides. Sequence varabilty within any of these
peptides between the env clones derived at 20 days and those from 6 months of age was
minimal , supporting the notion that these regions were not under selective pressure from an
immune response.
--,
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Interestingly, a portion of the amno acid sequence of peptide V3-
RPNNNTRKSI, was also reported by Safrit et a1 to be restrcted by HLA-B7 and
recognized by CTL clones derived from HLA-B7 HIV- l inected patients (9). Moreover
patient VI-06 possesses the B7 haplotype, whereas patient VI-OS does not. The A2
restrction of this molecule is questionable as it does not contain a discernible A2 binding
motif (139, 140). Therefore , an explanation for the lack of recognition of ths env peptide
by CTL precursors of patient VI-OS could be that ths patient simply lacks the appropriate
restrcting class I allele.
Sequences of viral varants derived from patients recognizing the V3- 1 peptide
demonstrated litte heterogeneity within this region, with complete conservation of the
putative anchor residues (P at position 2 and I at position 10). Comparsons of sequences
within laboratory virus strains UIB , RF, MN and SF2 revealed ths same conservation of
anchor residues. Indeed, the same is tre within the varants from both tie points
sequenced from patient VI-06. Only a sequence change of arginine to serine at position 9
(seen within a patient varant and HIV- IMN) could abrogate Cf recognition of ths
epitope but the effects of other amno acid changes on CTL recognition was not extensively
examned. This region appeared to be relatively well conserved in patient-derived vir
sequences from this study as well as in laboratory strains. It has been suggested that the
V3- 1 epitope would be useful for studying the cellular immune response to' candidate HI-
1 vaccines. However, we have observed that this region within viral variants from patient
VI-06 clearly evolved from relative homogeneity within the reported sequence to an amno
acid sequence quite different outside of the anchor positions. Conservation of the anchor
regions might stil allow for binding of this peptide to HLA B7 however, changes outside
of these positions might have resulted in escape from TCR recognition. Use of these
mutated peptides in detection of CI recognition by patient VI-06 is needed to confIrm or
deny this possibility.
' ,
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A porton of peptide 1930, KLTPLCVT, has been shown to bind with high
affinity to HLA-A *0201 and be recognized by er clones derived from patients
PQssessing ths allele (95). Therefore, the recognition of this peptide by per of patient
VI-06 is probably in the context of A2. The lower precursor frequency to ths peptide may
be due to irnunodominance of the B7 restrcted response to peptide V3-1. The lack of
recognition ofTI env by per ofVI-08 is surprising considering that ths patient' s vir
sequences demonstrate complete conservation of ths II peptide. These results suggest
that caution must be taen in using sequencing analysis of viral varants to predict 
reactivity. Clearly, other parameters need to be taken into account in addition to sImply the
presence or absence of a paricular epitope withn an individual with the appropriate class I
haplotype. Specificities of peptide transporter systems and the cellular proteolytc
machinery may also contrbute to the selection of er epitopes (141 , 142) as well as
po1ymorphisms in HLA class I alleles. For example , Bergmann et al (143) reported that
flanng residues can effect the presentation of HIV - 1 epitopes withn env to murine CTL.
In addition, Buseyne et al (144) reported differential recognition of gag epitopes withi::
CTL of patients who shared MHC alleles.
Lack of recognition of peptide 1923 in pCTL of patient VI-06 could be attbuted to
the choice of peptide used in the study. Previous studies have mapped A2 restrcted
recognition to the sequence LWVGVPVWKEA1TCA (8). However, finer
mapping by Dupuis et al (95) demonstrate high binding affinity and CTL recogntion of the
amno termnal porton of this peptide: KLWVVYYGV. The peptide used in detection of
pCTL of patient VI-06 was VPVWATIFCASDAKAY which includes almost none
of the smaller amno acid epitope. Again , proviral sequences of patient VI-08 contained
this nm based peptide sequence in the absence of pCTL recognition.
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1. ADCC antibodies directed against autologous and heterologous env protein.
Previous studies in our laboratory measuring ADCC antibodies in vertcally infected
infants demonstrated lack of detectable titers against heterologous env proteins following
the loss of maternal antibody. Most of the antibody detected from bir to12 months was
considered to be maternally derived and was usually group specific. Broliden et al (54) in a
study designed to exame whether there was a correlation between ADC antibody titers
and vertcal transmission , observed the same pattern in a tota of 35 mother-infant pairs.
ADCC antibody titers were measured against the II and RF strains of HIV - 1 though the
fIrst year of life in infected and uninfected infants and were compared with those of the
mother s. In each case , the antibody titer from the mother matched that of the chid though
the fIrst half year of life. Following this tie point, however, litte or no ADC antibody
was detected in these infants against HIV - 1 laboratory strains. They concluded, from ths
study, that there was no correlation between maternal ADCC antibody titer and vertcal
transmission of HIV - 1. In agreement with these studies, II-env-specific ADCC antibody
titers in plasma from patients VI-05, VI-08 and VI- II were low to undetectale by six
months of life and remained so out to 24 months of age which was the last tie point
examined in this study.
1. ADC titers of atient VI-06 The pattern of ADC antibody titers observed in
patient VI-06 was unlike any described in Broliden et al(48) or from the thee other
infant's studied here. Equivalent titers to both Hil and autologous 1 day env increased
dramatically from two months to six months of age and was therefore attrbuted to strong
antibody production by the infant within this early tie point. The strong recognition of
both heterologous and autologous envs is similar to the group-specificity of the 
response in ths patient in early infancy. Hypotheses concernng the possible
,.yj, . '--,
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circumstances mediating the broadly reactive nature of ths patient's imune response have
been discussed previously.
2. ADCC titers of patient VI- II specific ADCC antibody titers in the plasma
of patient VI-05 present at 2months of age ar close to that of autologous 2 month env.
However, nrn env ADC antibody titers dropped below detection by 6 months of age
while titers to autologous 2 month env remained the same. The loss of II env .A.DC
antibody at 6 months of age is consistent with the loss of maternal antibody, however, the
cQntinued presence of antibody to autologous 2 month env is indicative of an active
humoral immune response against that autologous virus. Patient VI-05 was a rapid
progressor who died by 22 months of age. The drop in ADCC antibody titers from 6 to 20
months of age could be reflective of disease progression as some studies have reported a
loss in ADCC responses with progression to AIS (53) although there is lack of agreement
on this subject. Ljunggren et al (145) observed that the presence of higher-titered ADC
antibody' in infants greater than 6 months of age correlated with a better clical prognosis.
ADCC antibody titers to 6 month autologous env and II were low to undetectable from 2
months to 20 months and 6 months to 20 months of age, respectively. This correlates with
the lack of CTL recognition of 6 month autologous env at these time points. However nrn
env is recognized by Cf at later time points in the absence of ADCC antibody recognition.
. The 6 month autologous env appears to have escaped both CTL and ADCC recognition. 
is possible that this was a minor varant withn the patient and was not present at high
enough levels to stimulate immunity. The discrepency between CfL and ADCC antibody
recognition of II env may be explained by epitope differences betweer. these two immune
responses. As this patient demonstrated only tye-specific ADCC antibody responses
subsequent to 2 months of age, the use of auto1gous env to measure ADCC antibody in this
patient demonstrated a pattern of antibody response which would have been missed if only
nIB responsiveness was assessed.
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3. ADCC titers of patient VI- ADCC titers present at 2 months of age in plasma
of patient VI-08 against both II env and autologous 20 day env dropped to nearly
undetectable levels by 6 months of age. This most likely represents a loss of maternal
antibody. An increase in titer against autologous 20 day env from 6 to 24 months
demonstrates the ability of ths infant to generate type-specific ADC antibody. Although
the autologous 6 month env and II env were recognized by CT from 19 months of age,
they faied to be recognized by ADC antibody afer 2 months of age. Again, different
regions of the env gene recognized by CT versus ADCC antibodies could account for ths
discrepancy. The lack of recognition of the autologous 6 month env may have resulted
from mutations withn the epitope(s) necessar for ADCC antibody production which
allowed for escape from recognition.
' ADCC titers of atient VI- II: Maternal ADC antibody titers appear to be
absent in patient VI- II represented by the complete lack of detectable ADC antibody to
TIIB or autologous 1 month and 3 month envs. This observation may be explained by
progressive disease in the patient s mother during the last trmester of pregnancy, however
no infonnation regarding this is available. Patient generated group-specific ADC
antibody began to appear between 6 and 12 months of age, although ADC titers were
higher against autologous envs. The group-specificity of the antibody response at 12
. months occurred at the tie of detection of more broadly reactive Cf although the
stronger recognition of autologous 3 month env is opposite of that seen by CT at this tie
point.
5. In utero vs intra arum timin of infection and induction of infant ADC
antibod res onses: Patients VI-05 and VI-06 are documented as having been infected in
utero. Because effcient placental transfer of antibody has been shown to occur within the
last trimester, infection may have occurred either before or afer the appearance of this
antibody within the fetus. In either case, mv - 1 specific antibody titers may have been low
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at the tie of infection. Je10nek et al (146) have demonstrated that the abilty of the
offspring of HIV - 1 env vaccinated mice to. mount HIV - 1 humoral responses upon
vaccination was inbited by the presence of maternal antibody. Reasons given for ths
inhibition include Fc-mediated inhbition , epitope masking and idiotypic pertrbation of the
infant's antibody response. Low titers of maternal antibody present at the tie of in utero
infection in infants VI-05 and VI-06 may have had less of an inhbitory effect resulting in
earlier anti-ID - 1 infant antibody responses. Therefore, the ADC antibody measured in
these infants at two months of age could be made up in par by antibody produced by the
infant. This could explain why a drop in antibody titer is not detected between two and six
months in these two infants.
Intraparm infection occurs following the completion of placenta transfer of
maternal . antibody . These high titers of antibody may inbit infant humoral responses
prior to its clearance from the plasma. This could account for the lag in antibody
production seen in patients VI-08 and VI- II. Although maternal antibody was not present
in patient VI- ll that was capable of mediating ADCC, overa titers of anti-HI- l env
antibodies transferred to ths infant could stil have been present. Positive anti-gpI20, -
. gp160 and -gp1 banding patterns on Western blot by sera from ths patient from bir to 3
months of age support this notion.
6 T e-s ecifici of infants .6IX:C res onses: These data indicate that the infant
is capable of generating ADCC antibody respons r to a year of life. The specificity of
these responses appears to differ from that of the Cf response in an intrapatient manner.
For example , patient '11- , who had group-specifc CT responses by 12 months of age
displayed only type-specific ADCC responses at and beyond this tie point. The same is
true of patient VI-08 who had UIB env responsiveness in the CT response at a tie point
where there were no ADCC antibody titers to this env. Whereas, the opposite is tre of
patient VI- II. With ths patient, ADCC titers were group specific from 6 to 24 months of
::', ;,. . \
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age while CT responses were ty-specific until 12 months of age. The early group-
specific imunity observed in patient VI-06 represents the only situation where the
specificity pattern cOITlated between ADC antibody and CI recognition. The V3 loop
is a region of the env gene which can serve as an epitope for ADC (50). In ths study,
CTL recognition ofVI-06 was mapped to a region of V3. Group specific responsivencss
in both CTL and ADCC antibody responses may be a result of a shared epitope in this case.
Env-specific antibodies detected by western blot in the first few months of life in
patient VI- II in the absence of measurable ADCC antibody titers suggests that there may be
limited regions of env to which ADCC antibody are directed. This could be due in par to
accessibility of epitopes beause of folding and oligireriation of env on the cell surface.
Synthetic pep tides which can compete for binding of antibodies and trncated env
expressing vaccinia vectors have been used to map the file specificity of ADC antibody
recognition. The last 46 amno acids of the carboxyl end of gp120 to the midporton of
gp41(147), two regions within the transmembrane of gp41(148, 149) and the V3 loop have
al been reported as ADC antibody epitopes (56). These have been mapped using adult
sera shown to be broadly group-specific. In young infants, theoretically, epitope
recognition may be more limited due to a the lack of primed B cells and memory CD4
helper cells. Limited recognition may also occur as a result of the young infant to recognize
. glycosy1ated regions of env. Infants lack T helper independent antibody production unti
approximately two years of life. These antibody responses are diected agaist
polysaccharde antigen. G1ycosy1ated regions of env may require a T helper independent
antibody response of which these infants ar incapable. Type-specific ADCC antibody
responses may be more commonly observed in early infancy as a result.
7. In vivo antiviral ADCC in infants: The potential therapeutic role of ADC
antibody in HIV- l infection in infants has not been clearly demonstrated. Jenkins, et 
(71) demonstrated a defect in neonatal peripheral blood mononuclear cells mediating ADC
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cytotoxicity although dict NK cytolysis appeared to be intact. Therefore
, although the
appropriate antibody may be present, the ability of the effector cells to effciently lyse
infected cells through an ADCC mechansm may be impaied. Deleterious effects of ADCC
antibody have been suggested as well. ADCC antibody may lyse uninfected CD4 cells
coated with soluble gp120 (150).
1. Implications for perinatal vaccination
Our results indicate that the young infant is capable of mounting HIV - 1 specific
immune responses. Vaccination of the infant at birth
, parcularly those exposed to HIV-
in the intraparm period, may be an effective strategy to interrpt transmission. One
would be stimulating immune responses in the infant at a tie when viral load is not only
low, but relatively homogeneous. In light of our recent findings concernng the type-
specificity of the immune response in early infante;
, the choice of viral strain for vaccination
wil be a complex issue. Had the intraparum infected patients described in this study (VI-
08 and VI- II) been vaccinated with a IIIB based env, en.. immunity iri response to this
env would probably not have cross-reacted with the transmitted virus
, and would not have
been protective. To manipulate CIL responses in vivo to respond dominantly to an
. invarant region of env one cauld use peptide-based vaccines. However, vaccines with
such limited epitopes could be ineffective in a number of infants due to HLA restrction
incompatibility. Administration of passive HIV -1 immunoglobulin at birt to prevent
infection and dissemination accompaned by repeated boostings within the fir:;t year of life
with var ng heterologous strains could possibly overcome this problem. Neonatal
delivery of passi'
.'e and active immunization has been shown to be successful in protection
from Hepatitis B infection. Successive immunizations would hypothetically be delivered
to an immune system which would be acquirng a broader spectrm of activated and
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memory per as the infant aged from which broader env specific responses would be
expected.
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